ANNUAL REVIEW 2022

Celebrating 10 years
2012-2022

TRI
TRANSLATIONAL RESEARCH INSTITUTE
AUSTRALIA

"Let their voices guide us and connect us to a healthier future."
Artwork by Wakka Wakka artist, David Williams

Acknowledgement of Country

We acknowledge the traditional custodians of the land we are on, and we recognise their continuing connection to land, waters and community. We pay deep respect to them and their cultures; and to Elders past, present and future.

The Translational Research Institute Australia (TRI) is one of the nation's youngest medical research institutes, having opened in late 2012.

TRI was constructed with a $356 million investment from the Queensland and Australian Governments; The Atlantic Philanthropies; Queensland University of Technology (QUT); and The University of Queensland (UQ).

Today it successfully operates as a unique collaboration between four major partners; The University of Queensland; Queensland University of Technology; Queensland Health and Mater Research.

The company Translational Research Institute Pty Ltd (known as TRI Corporate), in its capacity as trustee of the Translational Research Institute Trust, employs staff to manager and support the Institute's operations and advance its strategic goals.



Contents

TRI
TRANSLATIONAL RESEARCH INSTITUTE
AUSTRALIA

About TRI

The Translational Research Institute Australia (TRI) is the only facility of its kind in the Southern Hemisphere, and one of only a few places worldwide where new treatments, therapies and medical devices can be researched, discovered, manufactured and clinically tested in one location.

TRI is a unique ecosystem borne of a collaboration between UQ, QUT, Queensland Health and Mater Research. Located on Brisbane's Princess Alexandra Hospital (PAH) campus, TRI has more than 1100 researchers, clinicians, industry employees and corporate staff who support health discoveries from bench to bedside.

Cutting edge science, collaboration and innovation are championed at TRI by housing the brightest in academia, clinical experts, industry, start-ups and venture capitalists in one location, and within the footprint of two tertiary hospitals which ensures the seamless integration of research and clinical trials for both adults and children.

Supercharging this ecosystem are purpose-built facilities, world-class emerging technologies, and specialist staff support for areas like experiment design, grant and ethics applications, and data analysis. This is complemented by the clinical research facilities and services at the Princess Alexandra Hospital and Queensland Children's Hospital (QCH), which provide supports including trial design and advice, ethics and governance documentation, project management and patient recruitment.

Researchers, clinicians and industry have access to highly specialised resources which include laboratories (wet labs/PC2 labs); cGMP compliant cleanrooms (T3); eight core facilities boasting world class equipment and industry-leading expertise.

TRI sits at the interface of science, health care and its delivery, and industry.

Venture capitalists, sector advocates including Health Translation Queensland, and government platforms including NCRIS and MTPConnect, co-exist within TRI. Such remarkable accessibility drives acceleration, integration and collaboration.

This model bolsters early-stage pre-commercial startups such as EMVision, Infensa Bioscience, Microbio, Ocugene, Oroborus and has supported the international success stories of Vaxxas and Microba.

TRI also offers development to early and mid-career researchers (EMCRs) and students including translation coaching (Translation Pathways), consumer involvement training and a school-aged STEM program (SPARQ-ed). TRI grant schemes initiate collaborations between scientists and clinicians.

Looking ahead to 2023, TRI will be home to the Translational Science Hub – a collaboration between Sanofi, UQ, Griffith University and the Queensland Government to advance mRNA vaccine development.

By 2025, TRI will create an Australian-first translational manufacturing facility supporting mid-stage biotech companies toward product manufacturing for clinical trials. TM@TRI will leverage the research strengths and clinical synergies of TRI and its four partners.

As TRI's dynamic structure continues to grow and evolve, the Institute is well-placed to realise our shared vision of exceptional science, healthier lives.

OUR VISION

EXCEPTIONAL SCIENCE, HEALTHIER LIVES

OUR PURPOSE

TRANSFORMING HEALTH THROUGH COLLABORATIVE RESEARCH

OUR GOALS

PARTNERSHIPS, COLLABORATION, EXCELLENCE, RELATIONSHIPS

A message from the TRI Board Chair

Emeritus Professor David Siddle

Reflecting on the first decade, we can all be proud of the profound impact TRI has had, working alongside our shareholders and our partner organisations to advance translational research.

TRI's success bears testament to the power of collaboration. Creating a world-class research institute is not without its challenges. It has required relentless determination and a cooperative spirit from our shareholder leaders and our partner organisations. It has relied on wisdom and insight from successive Boards and on the dedication of CEOs and the senior management teams.

On behalf of the Board, I sincerely thank all our past and present collaborators who have made TRI into the powerhouse of translational research it is today.

Across 2022, TRI-based researchers, clinicians and industry members have worked hard to move past the obstacles posed by COVID-19, filling our laboratories, offices, meeting rooms and collaboration spaces with renewed vigour to effect the translation of innovative research into improved clinical practice, refined techniques and new products.

We also sought the endorsement of Reconciliation Australia for TRI's Reconciliation Action Plan to ensure that our organisation is lockstep with a wider community determined to create more equitable outcomes for all Australians. I congratulate the all-partner Working Group responsible for advancing this important project in 2022 and gratefully acknowledge the guidance of elders Aunty Beryl Meiklejohn and Uncle Charles Passi.

THIS YEAR, THE BOARD ENDORSED A NEW TRI STRATEGIC PLAN FOR 2022-2024.

Four key areas of focus were determined to help drive clear outcomes including:

Promoting thriving research, clinical and industry partnerships and creating points of interconnection through grants, purpose-driven programs or educational opportunities;

Fostering a collaborative environment for people and ideas to flourish, using the strong foundation created here in our first 10 years to harness new possibilities;

Achieving research excellence through access to world class capabilities and as we continue our quest for greater breadth, we move towards medical manufacturing; and

Strengthening relationships for investment in ideas, discovery and outcomes exemplified by our strong engagement with the Queensland Government.

Of course, there is still much to do to realise our ambitious vision. A satisfying coda to our first decade was securing a significant investment commitment from the Queensland Government to build TM@TRI. TM@TRI will be a stand-alone translational manufacturing facility whose central feature will be clean rooms of sufficient size to manufacture product for Phase III clinical trials.

As we close out our first decade, naturally we look ahead to what the next 10 years could hold. Fortuitously, TRI's 20-year milestone occurs as the eyes of the world focus on Brisbane for the 2032 Olympic Games. I have no doubt TRI will be well-positioned to translate that global interest into opportunity, championing more international collaboration and investment in Queensland's thriving life sciences sector.

In conclusion, I would like to thank my fellow Directors for their dedication and hard work on behalf of TRI.

CEO Update

Professor Scott Bell

Chief Executive Officer TRI

Despite a bumpy start to year three of the global pandemic due to the Omicron variant, there have been many extraordinary achievements to celebrate in 2022.

Most notable, TRI's 10 Year Anniversary, an event that united more than 300 of our OneTRI community to reflect on the journey to date. As part of that celebration, 90 of the TRI community who have been with us since the Institute's opening were acknowledged.

In 2022, our focus was firmly on the implementation of our new three-year Strategic Plan. Twelve months into that agenda we are well advanced across all four focus areas – partnerships, collaboration, excellence and relationships.

I am indebted to our Shared Leadership Group for helping us establish a connected and collaborative OneTRI culture. Our joint focus on EMCRs has led us to new professional development opportunities. Our Reconciliation Action Plan (RAP) Working Group another example of how united partners can help TRI deliver an ambitious agenda. Similarly, our Respect at Work committee achieved cut-through educating and training on important issues like Sexual Harassment Awareness and Prevention to create a safe, inclusive and diverse OneTRI community.

Our events, open to all TRI-based researchers and staff and industry partners, encouraged broad engagement. A highlight was the Translate 2022 conference which focussed on the nexus between MedTech industry and clinical trials, and fostering collaborations between researchers, clinicians and industry.

> Our Translation Pathways program introduced in 2022, has led to circa **$11.6 million in funding commitments** while consumer engagement has also been a priority with workshops for researchers, grant and document reviews, group tours and our TRI Consumer Forum.

Our OneTRI Awards also helped to facilitate an environment of reward and recognition.

An outstanding body of work has been delivered across the past 12 months in the Research and Clinical Translation area. Our TRI Grant Scheme continues to bear fruit with three project grants awarded in partnership with CSIRO and seven more through the 2022 LINC program. Discussions with UQ and the Queensland Department of Education in 2022 resulted in TRI assuming a hands-on role in SPARQ-ed - a good strategic fit to foster our next generation of researchers and clinicians.

Our Translation Pathways program introduced in 2022, has led to circa $11.6 million in funding commitments while consumer engagement has also been a priority with workshops for researchers, grant and document reviews, group tours and our TRI Consumer Forum. Across 2022, 10 Research Translation Committee Seminars and an Industry Meet & Greet were held. TRI-wide Town Halls plus our Researcher & Clinician Networking Series again supported collaboration and connection.

Our Industry Engagement team has strengthened partnerships with the MedTech and biotech sector and in 2022 TRI held two Biotech Stage events, conducted over 70 site visits alongside key stakeholders, and established a pipeline of commercial tenants for both TRI and TM@TRI.

TM@TRI has been an important strategic focus and I thank the TRI Board, our shareholders and the Queensland Government for their vision in supporting this unique, game changing project. Detailed designs have advanced, and a team of expert consultants appointed including Built and Savills.

TRI Corporate has evolved too following an executive restructure, with experienced corporate leader Karen Murphy now appointed to a new Chief Operating Officer role to lead a program of review.

A sincere thanks to our shareholders; our partners researchers, their leaders and teams; industry members of our OneTRI community, and to our TRI Corporate team. Our continuing collaboration ensures TRI is well placed to traverse the next decade.



10 Years of TRI

Australia's Translational Research Institute reached a major milestone in 2022, celebrating 10 years of operation. Since opening its doors in 2012, TRI has become the largest institute of its kind in the Southern Hemisphere, bringing together researchers, clinicians and industry to advance medical discoveries that lead to a healthier world.

To mark the occasion, the TRI community was invited to nominate the most significant translational achievements by a TRI-based researcher, clinician or commercial/industry group over the first decade.

While it may be one of the nation's youngest research institutes, the Top 10 Translational Achievements as selected by a cross-partner panel from a diverse and impressive list of nominations, demonstrate the depth of innovation and excellence emerging from the TRI community.

Former Governor-General Dame Quentin Bryce at the official opening of TRI in 2012.

Top 10 Translational Achievements

Centre for Personalised Analysis of Cancers

QUT's Associate Professor Elizabeth Williams was acknowledged for her work in bladder cancer and her key role in establishing the Centre for Personalised Analysis of Cancers.

Using genetic analysis, laboratory modelling, clinical trials and patient samples, her team is working towards providing clinicians with information to optimise and personalise cancer treatments—bringing the right treatment to the right person at the right time.

CPAC has now grown to include orthopaedic and upper gastrointestinal cancers, in addition to the original bladder, prostate, bowel, brain, breast, lung, and renal cancers, head and neck squamous cell carcinomas, and skin cancer / cutaneous squamous cell carcinomas.

New treatment for rheumatoid arthritis

UQ's Frazer Institute (UQFI) Professor Ranjeny Thomas and colleagues were acknowledged for developing a patented immunotherapy treatment for people with rheumatoid arthritis, which causes inflammation, pain and deformity due to their immune system attacking healthy tissues, especially joints.

New drugs are needed to reprogram the rheumatoid immune response and provide longer-term disease control than current medications.

The new immunotherapy was demonstrated to be safe and effective at modulating rheumatoid arthritis specific immune responses in Phase I clinical trials at the Princess Alexandra Hospital, in partnership with Janssen Biotech Inc.

Pictured Above - Left to Right; **Associate Professor Elizabeth Williams (QUT)**
Professor Ranjeny Thomas (UQFI).

Right page; **Professor Chamindie Punyadeera (QUT).**

Photo credit QUT

Saliva test for oral and throat cancer

Driven by the death of her young brother-in-law, Professor Chamindie Punyadeera and her team, then based at QUT, were acknowledged for the development of CancerDetect, the first saliva-based test of its kind to detect biomarkers associated with early-stage oral and throat cancer.

Throat and oral cancers are often diagnosed late, leading to low survival rates. It's hoped that this test will lead to earlier detection for people at risk, such as those people who smoke or are aged over 50.

US-based biotech company Viome has commercialised the test, which can be ordered online.

Microba's technology provides testing to clinicians, consumers and research customers world-wide. And now with an established bench of leading international healthcare providers, Microba's tests can be accessed in more than 35 countries.

Pictured Above Left: **Professor Philip Hugenholtz, Microba Life Sciences Co-Founder.**

Top 10 Translational Achievements

Microba Life Sciences

Microba Life Sciences, and their founding team, including QUT Prof Gene Tyson, UQFI Professor Philip Hugenholtz, Dr Nicola Angel and Dr David Wood were recognised for their work on the gut microbiome.

Over the last decade, a growing body of research has demonstrated that the gut microbiome plays a critical role in many aspects of health and disease, but current technology lacks the ability to accurately map these relationships.

The team addressed this gap through the development of Microba's world-leading technology for measuring the human gut microbiome and aim to advance the clinical application of microbiome testing to become embedded as a routine part of health and disease management.

Microba successfully listed on the ASX in 2022 raising $30M and now employs more than 70 staff.

Revolutionising Accessibility of Generic Medicines

UQFI's Dr Yousuf Mohammed, Dr Sarika Namjoshi and Emeritus Professor Michael Roberts were acknowledged for their work with the US Food and Drug Administration (FDA) on improving the accessibility of affordable topical medications by revolutionising the way generic products are regulated. Their research has directly supported new paradigms for topical and transdermal drug development, with a corresponding modernisation of regulatory standards. As an outcome it is now possible to predict and control the performance of semisolid products. In the US and Europe alone, more than 80 regulatory guidelines now recommend the use of these new techniques to develop topical and transdermal products.

Sulphate: critical for baby brain development

Mater Research's Dr Paul Dawson and colleagues, with the support of Dr Elizabeth Hurrion, were recognised for their work demonstrating the importance of sulphate in neonatal brain development, which led to a world-first test now available for routine clinical use.

Preterm babies become sulphate deficient after birth, which is proposed to increase the risk of cerebral palsy. Dr Dawson's research showed that sulphate is critical for neurodevelopment, which is underpinning his ongoing research in the field.

Top 10 Translational Achievements

Vaxxas: Needle-free vaccination

Vaxxas is focused on enhancing the performance of vaccines and increasing access to vaccination with its needle-free vaccine skin patch. Covered in thousands of tiny vaccine-coated microprojections, the technology has the potential for self-administration and is designed to be stored at room temperatures, eliminating the need for cold-chain storage and distribution.

Founded in 2011 on research at The University of Queensland, Vaxxas has been a key tenant of the TRI since 2015, rapidly translating from a small university-based entity to a scale-up biotech company. In 2023, the company intends to open its first manufacturing facility in Brisbane, but will maintain an important footprint at TRI enabling preclinical studies to advance its product pipeline.

A new treatment for acute myeloid leukaemia

Mater Research Associate Professor Ingrid Winkler discovered a new strategy for improved leukaemia treatment and formed a partnership with US drug company GlycoMimetics to translate the findings together. GlycoMimetics had developed an antagonist drug Uproleselan.

Early clinical trials in patients suggested administering Uproselesan at same time as chemotherapy may improve leukaemia therapy. This led to larger Phase III clinical trials currently in progress in Australia and the US.

Around 900 patients in Australia are diagnosed with acute myeloid leukaemia each year. Prognosis can be poor as chemotherapy alone may often not be effective.

Pictured Above: **Vaxxas device; Associate Professor Ingrid Winkler (Mater Research).**



New technology to detect melanoma

UQFI Professor Peter H. Soyer, UQ Centre for Health Services Research (UQCHSR) Professor Monika Janda, Mrs Liz Payne, and the broader team from the Dermatology Research Centre were acknowledged for their clinical implementation of VECTRA Whole Body 360, an imaging technology for early detection of melanoma for high-risk patients.

The VECTRA imaging system uses 92 cameras to construct a 3D avatar of a patient with detailed reproduction of the skin.

This record of the patient's whole skin surface can be used as a reference during follow-up visits, revolutionising the way skin cancers and conditions are mapped, monitored and diagnosed.

Top 10 Translational Achievements

A boost to understanding and treating post-transplant lymphoma

Mater Research Professor Maher Gandhi and UQFI Dr Colm Keane were acknowledged for their ground-breaking discoveries of viral and non-viral-associated lymphomas, leading to the development of a new treatment regime for viral-associated lymphomas and a reclassification of these lymphoma types by the WHO.

They discovered that viral-associated lymphomas had distinct features from non-viral lymphomas, that enabled them to be targeted with a novel combination of treatments. This is particularly relevant for patients with post-transplant lymphoma, which is a complication that can occur in patients who have had kidney and liver transplants.

Their new therapy regime has also been shown to induce long-lasting remission in patients with refractory lymphoma and is becoming widely used in Australia for patients with viral-associated brain lymphomas.

Ground-breaking discoveries of viral and non-viral-associated lymphomas, leading to the development of a new treatment regime for viral-associated lymphomas and a reclassification of these lymphoma types by the WHO.

Pictured Above: **Dr Colm Keane (UQFI).**
Right Page: **Muhammed Sabdia and Professor Maher Gandhi (Mater Research).**


TRI
mater research
TRI
partnering for better health
Mater
Research

Strategic Plan 2022-2024

PARTNERSHIPS

Promote thriving research, clinical and industry **partnerships**

Key Strategies

- Map TRI research capabilities and capacity to national health priorities to enable and facilitate collaboration (1).
- Increase connections for TRI-based scientists with clinicians and industry (2-5).
- Collaborate on grant opportunities (including Medical Research Future Fund) to address important clinical questions (1-3).

COLLABORATION

Foster a **collaborative environment** for people and ideas to flourish

Key Strategies

- Promote a 'OneTRI' culture through the creation of joint opportunities, initiatives and shared collaborative spaces (1-5).
- Provide a workplace that values safety, diversity, inclusion, health and wellbeing (1-3).
- Support, train and mentor our people to increase translational capability and to promote career success (4, 5).

EXCELLENCE

Achieve research excellence through access to **world class capabilities**

Key Strategies

- Maintain and facilitate access to cutting edge research infrastructure for TRI researchers and for our collaborative networks in Queensland (1-3).
- Develop and publicise TRI-based research excellence, infrastructure and capabilities (1, 2, 4).
- Provide opportunities to increase capability of TRI research support and professional staff (4, 5).
- Deliver and support novel investigator-initiated, MTP industry and sponsored clinical trials (1-3).

RELATIONSHIPS

Strengthen **relationships for investment** in ideas, discovery and outcomes

Key Strategies

- Promote a strong, cohesive TRI through its influence nationally and internationally by collaboration with health and medical research organisations (1-3, 5)
- Build sustainable relationships with industry and peak industry bodies (4, 5).
- Engage with community consumer networks (3, 5).
- Foster relationships with governments (5).

Following wide consultation with the TRI community a new Strategic Plan for 2022-2024 commenced on 1 January, focusing on four goals: Partnerships, Collaboration, Excellence and Relationships. The Shared Leadership Committee (SLC), the Executive Leadership Team (ELT) and the TRI Corporate managers have each worked on key priorities across 2022 for the implementation of the Strategic Plan, with OneTRI the focal point.

As with all organisations, the Strategic Plan will continue to evolve to ensure TRI continues to deliver world-class health research that is based on the latest research and community need.

Success Measures

1. Growth in the number and diversity of multi-partner collaborations measured by co-publications and joint grant applications by TRI-based researchers.
2. Growth in the number of TRI affiliates (across clinical, research and industry domains).
3. Increased TRI-based researcher collaborations with industry.
4. Increased TRI-based researchers participating in translational training programs
5. Ongoing engagement and linkage with startup/scaleup commercial companies based at TRI and nationally.

Success Measures

1. Gender equity is represented on TRI committees and speakers/chairs at TRI-wide seminars.
2. Expanded TRI Wellbeing Committee representation to embed a OneTRI culture
3. Growth in the number of, and participation rates in, TRI-wide wellbeing events and initiatives.
4. Growth in the number of participants in targeted TRI-wide mentoring and career development programs for EMCRs.
5. Improvements to TRI's collaborative built and social environment informed by feedback from experience and exit surveys.

Success Measures

1. Growth in utilisation of core facilities, including cleanrooms and clinical research facilities by (i) internal users and (ii) external users.
2. Increased satisfaction of users of the TRI (i) core facilities and (ii) clinical trial facilities.
3. Growth and diversity of translational trials, both in (i) investigator-initiated clinical trials and (ii) industry-led clinical trials.
4. Growth in the number and dollar investment of successful joint infrastructure programs at TRI.
5. Improved retention rates and job satisfaction of research support and professional staff at TRI.

Success Measures

1. Increased international collaborations measured by numbers of (i) publications and (ii) international grant applications.
2. Growth in the number of TRI-based occupants on key health and medical research state and national committees.
3. Growth in the number of TRI-based researchers undergoing consumer engagement training.
4. Growth in the number of TRI-based researchers collaborating with TRI-based and / or other companies in industry.
5. Maintain and encourage a diverse range of high-profile visits (including government, industry, university, MRI peers and international researchers) to TRI and develop associated media and social media activity.

World Class Facilities@TRI

TRI is a one of the largest medical research institutes in the southern hemisphere. It combines world-class laboratory and clinical translational research facilities, small scale manufacture facilities for medicines and devices, along with company incubator and educational spaces to seamlessly advance medical discoveries to healthcare solutions.

Architecturally designed to inspire collaboration, the main TRI building is located adjacent to the Princess Alexandra (PA) Hospital in Brisbane. It incorporates four floors of state-of-the-art laboratories, plus three floors for research support, administration and teaching.

World-class, emerging technologies are available to all researchers through shared specialist Core Facilities offered by TRI. Highly specialised equipment and expert staff are available to both internal and external researchers and institutions.

TRI is also home to eight scale-up and early-stage MedTech, biotech and pharmaceutical companies, as well as providing office space to a further six biotech sector service providers.

In addition to the main building, TRI has established two specialised clinical trial units, one at the PA Hospital and one at the Queensland Children's Hospital.

All of TRI's specialised research, clinical trial and event facilities are available for use at tiered fee rates for researchers based at TRI Partner Institutes, external academic researchers and commercial organisations.

In 2022, TRI continued its ongoing investment in these facilities to ensure its researchers have the best quality infrastructure and equipment at their disposal.

32,000m²
TRI BUILDING

T3Cleanrooms

TRI provides the infrastructure and regulatory compliance necessary for the small-scale manufacture of medicines and devices for human use. Our current Good Manufacturing Practice (cGMP) cleanroom facility is available for use by TRI researchers and early-phase biotech companies. This facility is ideal for producing clean to sterile medical devices, biotechnology, pharmaceutical and cell-based products for human clinical studies.

Launched in 2020, this is the only facility of its kind in Australia for the medical technology and pharmaceutical sector.

Through this hub, TRI is accelerating the translation of new medicines and devices for early-stage clinical trials.

In 2022 TRI continued a collaboration with the Centre for Biopharmaceutical Excellence (CBE) on the successful GMP Uplift Program.

The program provides participants with real-world perspective on GMP and is designed to assist with the interpretation and application of GMP into practice for those involved in human health products. In 2022, a total of 77 people participated in this cleanroom/GMP training. Which included 21 researcher-based participants and 36 from industry-based roles, from within TRI or across SEQld.

This program is supported by MTPConnect's Researcher and Development Within Industry (REDI) initiative, funded by the Medical Research Future Fund (MRFF).

TRI is one of only three training sites nationally and this work represents the final milestone in the federally funded TRI/ Vaxxas/MTPConnect TRI T3-Cleanroom upgrade grant.

Two clinical trial facilities at the Princess Alexandra Hospital (PAH) and the Queensland Children's Hospital

GMP cleanrooms for small-scale regulatory-compliant product manufacturing

200 EVENTS held within professional conference-style facilities on site to further research collaboration

$24.3M in shared Core Facilities equipment and 43 Core Facilities staff

SPARQ-ed's purpose built education outreach space had 1550 students visit

Flexible office and lab space

World Class Facilities@TRI /

Core Facilities

TRI Core Facilities provide dedicated research equipment, valued at more than $24.3 million, to further translational research. Both internal and external researchers can access these facilities.

The equipment, is fully supported by 43 technical and laboratory staff across seven areas:

FLOW CYTOMETRY

MICROSCOPY

HISTOLOGY

Annually, TRI invests in its Core Facilities with a program of infrastructure review and investment, to ensure both the replacement of ageing essential equipment and to meet emerging research needs.

PROTEOMICS



PRE-CLINICAL IMAGING

BIOLOGICAL RESEARCH FACILITIES

GNOTOBIOTICS

FLOW CYTOMETRY

Flow Cytometry is a widely used and highly versatile technology for studying the characteristics and/or biological functions of cells. By using cell-sorting systems, it is possible to separate out specific cell types for downstream research applications.
The TRI Flow Cytometry Suite is well known within Queensland for its high-quality equipment, expertise, and customer service for both TRI and external researchers. The facility also supports a suite of computers with a range of software for data analysis, and staff are available to consult regarding experimental design, sample preparation, panel design and data analysis.

World Class Facilities@TRI / **Core Facilities**

MICROSCOPY

The TRI Microscopy facility supports an array of instruments for the generation of high-quality reproducible images. Capabilities include: slide scanners; upright and inverted fluorescence and brightfield microscopes; live cell imagers; laser scanning and spinning disc confocal; and super-resolution and multiphoton microscopes. The facility also supports downstream data analysis and processing utilising high-end ICT infrastructure and a range of analysis software. Facility staff provide the expertise to assist with all aspects of image generation - from experimental design and equipment selection to analysis and preparation of publication-ready images.

HISTOLOGY

Histology is an essential foundational technique for many biological scientists and clinicians, allowing them to visualise and better understand the microanatomy of cells and tissue. As a research-based Histology core, the facility offers a range of standard services, as well as working directly with researchers to develop and optimise specialty solutions to experimental questions. Both full-service and self-service modes of operation are supported, with the facility providing training and access to a range of specialised equipment for work with paraffin and cryo-embedded samples.

World Class Facilities@TRI / **Core Facilities**

PROTEOMICS

Proteomics is the study of proteins in a system. Modern proteomics techniques use Mass Spectrometry to identify, quantify and characterise large numbers of proteins from target samples. Researchers can gain significant insight into the biological function and changes within cells and tissues as a result of different disease or treatment conditions by using proteomics. TRI's Facility provides both full-service and self-service options including assisting with project design, sample analysis, access to specialised equipment and computing resources, as well as training and support.

PRECLINICAL IMAGING

Preclinical Imaging is an invaluable bridging technique for research into animal models, providing access to clinically relevant technologies that mirror those available within healthcare settings. The Preclinical Imaging Facility provides researchers access to a variety of high-end in vivo and ex vivo imaging instruments, as well as offering targeted radionuclide therapy as a service. Facility staff are heavily engaged in project design and development, provide support for grant writing and animal ethics applications and deliver comprehensive hands-on training on image acquisition and data analysis.

BIOLOGICAL RESEARCH FACILITY

The Biological Research Facility provides high-quality research support and animal husbandry for TRI. It was developed to enable effective research whilst also ensuring the humane care and use of animals to advance human treatments and therapies.

GNOTOBIOTICS

Gnotobiotic facilities are highly specialised and sought-after capabilities, in part due to the rise of the microbiome as an area of vital health importance. TRI's facility is the only one of its kind in Queensland, and only the second facility to be established within Australia. Gnotobiotic (defined flora) and Germ-free (sterile) mice have research applications in many fields of medical research including allergy, cancer, autoimmunity, and GI disorders. The facility provides a full-service experience assisting with experimental planning and implementation, training of researchers, Gnotobiotic logistics and animal ethics advice for researchers.

Findings open way to treat debilitating spinal injury complication

Mater Research Professor Jean-Pierre Levesque (pictured) and his team are world-leaders in neurogenic heterotopic ossification (NHO) research, a debilitating condition that affects one in five people with brain or spinal injury.

NHOs occur when the body starts producing bones within soft tissues, usually in muscles around joints such as hips and knees. The condition can cause extreme pain and can eventually lead to the joint being encased in bone and completely restricted from movement.

By accessing the highly specialised equipment and expertise available through TRI Core Facilities, Professor Levesque's team were able to identify the cellular processes involved in the development of NHOs, and the role of the immune system and stress hormones in triggering these processes.

Critically, they were also able to identify the cells within injured muscles that were incorrectly being reprogrammed to produce bone, paving the way for new therapeutic strategies.





World Class Facilities@TRI / **SPARQ-ed**

The Students Performing Advanced Research Queensland Education (SPARQ-ed) project is an educational outreach collaboration between the Queensland Department of Education and UQ.

SPARQ-ed facilities include a classroom and PC2 laboratory – located on Level 2 at TRI – accessible to high school students and staff across Queensland.

Through its programs, SPARQ-ed delivers sustainable and accessible world-class biomedical education experiences to inspire students to consider STEM subjects and careers, enhance the professional practice of teachers and build strong connections with the community.

During 2022, SPARQ-ed ran seven, five-day 'Research Immersion' programs, 46 excursions at TRI, and 19 incursions (two-hour school visits), as well as four professional development sessions for teachers and science technicians. Overall, the program saw 1550 secondary students visit TRI.

In 2023 TRI will assume responsibility for the SPARQ-ed collaboration alongside the Department of Education.

World Class Facilities@TRI / **Event Spaces**

To encourage collaboration, TRI has a range of beautiful and functional professional meeting spaces available for use by building occupants as well as for hire by external organisations. Event spaces include a 250-seat auditorium, seminar and student rooms, and TRI's biophilic design centrepiece - an open-air atrium.

The TRI Communications and Marketing team provides logistical and booking support to users. During 2022 the team supported 60 TRI-led events, 112 internally booked partner events, and 30 externally booked events.

Research@TRI

2022 HIGHLIGHTS

- **$39M+** in research grants
- **38** researcher awards
- **591** research publications
- **4,296** citations
- **411** publications in journals in the top quartile for its subject
- **21** in top 1%
- **89** publications mentioned in 513 news outlets
- **43** publications with an industry partner
- **345** publications with an international collaborator

TRI's mission is to improve the translation of innovative research into clinical practice. To achieve the level of collaboration needed, TRI provides world-class research facilities; links to clinicians and clinical trial facilities and expertise; access to industry, government and other funding bodies including venture capital funds; and education and training programs aimed at producing a skilled workforce for the translational pathway.

The focus of TRI-based research is deliberately broad with the intention of having strategically important areas of health research reflected here. In 2022 the work of TRI-based researchers from our four partners (UQ, QUT, Mater Research and the Queensland Government's Metro South Health) has broadly focused on: immunology of disease, cancer, chronic and severe diseases, and neurosciences.

Research@TRI / **2022 Grants**

$39M was awarded in 79 new research grants in 2022 for TRI-based researchers. This included nine from the National Health and Medical Research Council (NHMRC), six from the Medical Research Future Fund (MRFF), eight from the Australian Research Council (ARC), and three from the US Government.

$2.8M MRFF BOOST FOR VITAL CANCER IMMUNOTHERAPY RESEARCH

The MRFF awarded $2.8 million to Mater Research Professor Maher Gandhi and his TRI-based team to trial a new immunotherapy to treat a rare but devastating blood cancer.

The ground-breaking Australasian Leukaemia Lymphoma Group Phase I study will use frontline immunotherapy to target the unique viral-immuno-biological features of Epstein-Barr virus-associated Diffuse large B-cell lymphoma.

This type of lymphoma is rare and has high rates of relapse and very poor survival rates. There is currently no effective treatment against the disease.

Professor Gandhi, who heads the Blood Cancer Research Group at TRI, said the five-year MRFF grant provided a welcome boost to his research.

"We want to provide a highly targeted but relatively well-tolerated therapy that eradicates disease and prevents relapse by restoring immunity," Professor Gandhi said.

Research@TRI / **2022 Awards**

Associate Professor Helen Benham

In 2022, 38 partner researchers based at TRI received awards. Highlights among a long and distinguished list included:

- QUT's Eamonn McKenna becoming Fulbright Future Scholar;
- Associate Professor Helen Benham, named Chief Executive Women's STEM Scholar 2022;
- Mater Research/UQ's Chloe Yap, winner of CSL's Florey Next Generation Award; and
- MSH's Professor Carmel Hawley's TJ Neale Award from the Australian and New Zealand Society of Nephrology for her contributions to nephrological science for more than 12 years.

Two new Fellows were also appointed by the Australian Academy of Health and Medical Sciences – TRI-based UQFI Professor Di Yu and member of the Shared Leadership Committee, QUT Distinguished Professor Patsy Yates AM.

REDI FELLOWSHIP TO ADVANCE PROSTATE CANCER DETECTION

TRI-based Professor Jyotsna Batra (pictured) from QUT will work with global MedTech company, TissueGnostics on developing antibody technology for prostate cancer detection.

The Researcher Exchange and Development within Industry (REDI) Fellowship program provides up to $250,000 per Fellow to provide industry experiences and professional development to strengthen Australia's successful translation and commercialisation of medical research.

Professor Batra is a geneticist who uses genetic and bioinformatics analysis to define disease risk.

She began developing a tissue multi-staining kit and corresponding AI-based analysis software with TissueGnostics in Vienna, Austria, from mid-2022.

She will then use the antibody technology to develop new diagnostic or prognostic biomarkers for prostate cancer. The technology will also be applied to her research group's discovery of DNA variations linked to prostate cancer, including a prostate specific antigen gene variant that impacts current clinical testing accuracy.

"I have pursued many opportunities over the past few months that I would never have dreamt of pursuing had it not been for the coaching. Thank you again for the opportunity - I am convinced that in years to come, I will look back on it as a career game changer."

Dr Aideen McInerney-Leo (UQFI)

Research@TRI / Translation Pathways

The Translation Pathways program is designed to help early and mid-career researchers and clinicians harness the potential of their research and fast-track the journey from discovery to bedside.

Specific outcomes include developing the tools and skills to understand how to design projects with a translational outcome in mind; skills to connect with key stakeholders early to inform, direct and potentially fund their research; and accelerating translational research outcomes.

The schedule for 2022 consisted of three training and coaching modules including focus workshops and one-on-one coaching.

There were 25 participants for the program in 2022 and this group collectively went on to achieve ~$11.6 million in new/commitment to funding.

Research@TRI / Consumer and Community Involvement

At TRI, we believe in the value of integrating health consumers' lived experiences, perspectives, and feedback to help shape health research. We are committed to working in partnership with TRI-based researchers and clinicians, health consumers and community members to make better decisions, formulate relevant priorities and practices, and adopt learnings into better outcomes for our communities.

TRI launched a Consumer & Community Involvement (CCI) Program in 2022 to support TRI-based researchers in developing successful partnerships and collaborations with health consumer networks and fostering stronger relationships in the community nationally.

The program includes:

- Researcher workshops focused on consumer involvement in the development of research projects
- Support and training for health consumers interested in being involved in research
- Public tours of TRI facilities
- Consumer and researcher engagement and network events

TRI is invested in nurturing these partnerships and recognises the value of contributions provided by health consumers through these connections. Health consumers include people who have experience, either personally or in caring for others, in an area of health. This lived experience can help prioritise research according to patient needs. By engaging with members of our communities in this way, we can discover answers to many of our research questions and translate this knowledge into better patient care.

Research@TRI /
Clinical innovation programs

Through discrete funding and in-kind support for clinician-led innovation programs, TRI has been actively helping build translational research through the clinical interface. In 2022, TRI continued its support for four clinical innovation programs.

Australian Centre for Complex Integrated Surgical Solutions (ACCISS)

Established at TRI in 2019, ACCISS is a multidisciplinary department that helps clinical teams better understand and solve complex medical challenges, as well as supporting patient education and the training of junior medical, nursing and health professionals using new and emerging technologies, particularly in the field of three-dimensional (3D) printing.

Its services include:

1. The design and development of reference anatomical models; patient-specific splints and prosthesis; and patient-specific surgical cutting guides, customised surgical tools as well as a wide range of assistive medical devices.

2. A physical and virtual surgical planning service using 3D printing, virtual and augmented reality technologies to improve clinician assessment and evaluation of complex cases for the purpose of enabling reduced operating time and better clinical outcomes for the patient.

3. Collaboration with industry partners to develop and test medical devices that are still in clinical trials.

Pictured Above: **Dr Michael Wagels, Director of ACCISS**

Diagnostic Imaging

In 2022, TRI continued its funding of Director of Imaging Technology, Professor Graham Galloway (pictured). This role has been funded since 2016 and focuses on novel breast cancer imaging technologies and the use of advanced MRI technologies for a range of clinical disorders including psychiatry, neurology, brain injury and trauma.

Professor Galloway is also the Academic lead for the TRI Preclinical Imaging facility and provides mentoring and strategic advice to the team. This, combined with his work as a Director the Herston Imaging Facility (HIRF), demonstrates Professor Galloway's dedication to translation, ensuring clinicians are directly engaged in the research agenda while providing them with the opportunity to evaluate newly developed technologies in controlled environments. HIRF provides an evidence-base for new and improved treatments, with this partnership approach ultimately leading to more cost-effective health care and improved clinical outcomes.

Familial Breast Cancer Clinic

The Preventative High-Risk Familial Breast Cancer Clinic at the Princess Alexandra Hospital is advancing the benefits of world-leading research so that patients with a high risk of cancer receive predictive analysis and early intervention.

The clinic harnesses research from TRI in MR spectroscopy to predate and predict the onset of cancer for those women with familial risk with the BRCA1 gene mutation.

TRI supports a PA Hospital Research Fellow to ensure links with breast cancer researchers at TRI, which includes formal mentoring in research methodology.

Microbiome Research

TRI contributes to provide funding for microbiome research led by UQFI Chair, Microbial Biology and Metagenomics, Professor Mark Morrison.

UQFI's Professor Morrison (pictured) has worked closely with staff from the Germ Free and Gnotobiotic Facility and other TRI-based scientists in advancing their capability for microbiome-based manipulations of animal models. This includes their access to and training in the use of specialised equipment for the management and growth of fastidious anaerobic bacteria, critical for the successful colonisation of animals and biobanking of microbiome samples.

His team has developed and validated the preservation of tissue biopsies collected in a clinical setting for bringing microbial genomes to life. The approach enables for the first time the holistic recovery and deep characterisation of viable forms of the microbial communities attached to gut tissue in health and disease. These communities are known to be different from those in stool samples, but their involvement in the pathogenesis and potential treatment options for digestive diseases has been elusive. These methods are being utilised as a central plank of his studies with TRI-based, national and international clinician scientists, focused on inflammatory bowel diseases and disorders of gut-brain interactions.

Professor Morrison has sustained funding from the Australian Research Council, Medical Research Future Fund, NHMRC, and philanthropic sources for his research, and continues as Australia's science representative to the International Human Microbiome Consortium and basic science lead for the Princess Alexandra Hospital's Department of Gastroenterology and Hepatology.

He was also elected Fellow of the Queensland Academy of Arts and Sciences in 2022.

Skin cancer cream for organ transplant patients



Immunosuppression in organ transplant recipients greatly increases their risk of keratinocyte (non-melanoma) cancer. These patients are 100 times more likely to develop skin cancers than the general population, making it one of the leading causes of death for organ transplant recipients in Australia.

UQFI Professor Kiarash Khosrotehrani (pictured), Dr Lea Dousset and their team are clinically testing a topical sirolimus cream to prevent facial skin cancers in this vulnerable population.

Sirolimus is used orally in organ transplant patients as an anti-rejection medication and to prevent the onset of skin cancer, but it is poorly tolerated. In a pilot study, the team found the cream was effective at fighting the early cancers without major side effects.

Professor Kiarash Khosrotehrani said the cream could be a game changer for transplant patients across the globe.

"Our research showed a three-to-four-fold reduction in early skin cancers in patients who used the cream on their hands and forearms. It also had minimal side effects and didn't impact the commonly prescribed anti-rejection drugs," Professor Khosrotehrani said.

The research team was awarded $2.5 million from the Medical Research Future Fund to undertake a clinical trial of the new cream called 'Siroskin' with 150 participants across Brisbane, Sydney and Melbourne.

The pilot study was funded by Metro South Health's Study, Education, and Research Trust Account (SERTA) scheme and published in November 2022 in the Journal of the American Academy of Dermatology.

Discovery boosts hopes of preventing Type 1 diabetes

Mater Research and UQFI scientists based at TRI may be a step closer to preventing Type 1 diabetes after identifying a crucial protein that could prevent the autoimmune disease from taking hold.

Researchers have developed a biological agent, sRAGE, that boosts white blood cell function which is damaged in individuals who develop Type 1 diabetes.

Senior study author, Mater Research Professor Josephine Forbes (pictured), said the protein discovery was an exciting development.

"Our laboratory tests show sRAGE can correct faulty regulatory T-cells to better prevent the immune system from going haywire and causing diabetes," Professor Forbes said.

"Our pre-clinical studies indicate this agent will be safer and far less intrusive than current treatments being tested for Type 1 diabetes prevention.

"We've already started working with companies overseas to explore ways of delivering the treatment in tablet form and we're optimistic about starting clinical trials within three years."

The research findings have been published online in the American Diabetes Association journal, Diabetes.

The study was funded by Mater Foundation, Juvenile Diabetes Research Foundation and the National Health and Medical Research Council of Australia.

Study reveals how COVID-19 damages the heart

A team of international researchers, including some based at TRI, have discovered how COVID-19 damages the heart, opening the door to future treatments.

UQFI's Dr Arutha Kulasinghe (pictured) and team were able to demonstrate for the first time at the molecular level, the different effect that COVID-19 and influenza can have on cardiac tissue.

"Compared to the 2009 flu pandemic, COVID has led to more severe and long-term cardiovascular disease but what was causing that at a molecular level wasn't known," Dr Kulasinghe said.

"During our study, we couldn't detect viral particles in the cardiac tissues of COVID-19 patients, but what we found was tissue changes associated with DNA damage and repair.

"DNA damage and repair mechanisms foster genomic instability and are related to chronic diseases such as diabetes, cancer, atherosclerosis and neurodegenerative disorders, so understanding why this is happening in COVID-19 patients' heart tissue is important."

UQ's Professor John Fraser, who established the international COVID-19 Critical Care Consortium, said the findings provided insights into how COVID-19 impacted the body compared to other respiratory viruses.

"What we have categorically shown is that COVID is not 'just like the flu'.

"This study helps us understand how COVID-19 affects the heart, and that is the first step in working out what treatments might work best."

The international team also included UQ's Dr Fernando Guimaraes, Professor Gabrielle Belz and Dr Kirsty Short, Ning Liu and researchers from WEHI, as well as the Critical Care Research Group at the Prince Charles Hospital.

The research was published in Immunology.

New portable tech helping young women understand their breast cancer risk

Australian women of all ages, including those in rural and remote areas, could better gauge their breast cancer risk sooner through new imaging technology developed at TRI.

Women with dense breast tissue have a considerably higher risk of developing cancer compared to those with less density. They are also more likely to have cancers missed on their mammogram, because their density can hide the cancer.

Study leaders QUT's Dr Konstantin Momot and Professor Erik Thompson (pictured) initially found that a portable nuclear magnetic resonance (NMR) machine could precisely measure breast density without harmful ionizing radiation. They previously published their findings using laboratory samples, and now have shown it in 15 healthy women volunteers.

"Once further optimised and developed, the portable NMR will give us a two-dimensional image of the breast tissue and its density, which ultimately will allow women to better gauge their overall risk early," Professor Thompson said.

"Portable NMR could be used in measuring breast density in young women where mammography isn't recommended – or in women where mammography is not suitable.

The volunteer study paper was published in the journal Magnetic Resonance Imaging.

181
Clinical Trials

46
New Clinical Trials
opened in 2022

Translational Trials supported
32
Clinical Trials

CRF hosted or supported
54
Industry Partners

Clinic@TRI

TRI's Clinical and Research Translation business unit is responsible for enhancing the interface between TRI and clinical care delivery.

To support the translation of scientific discoveries to patients, TRI runs two state-of-the-art, purpose-built and fully staffed clinical research facilities along with a trials-specific support team, known as Translational Trials.

Clinical researchers and Principal Investigators (PIs) can request access to the trial facilities and the Translational Trials support team to conduct clinical trials in a safe, secure and welcoming environment.

In 2022, the CRF and TRIC were the sites for 181 clinical trials, including 46 new trials commencing in 2022 and the remainder being ongoing trials.

The Translational Trials team supported 32 trials in 2022 in the therapeutic areas of ophthalmology, bladder cancer, brain cancer, complementary medicine, COVID-19, gastroenterology, endocrinology, head & neck cancer, hepatology, intensive care, imaging, lung cancer, pain, prostate cancer, rare cancer, reconstructive surgery, nerve regeneration, respiratory, skin cancer, solid tumour cancer, surgery, and vaccine delivery.

Clinic@TRI /
Clinical Trial Facilities

TRI's Clinical Research Facility (CRF) and TRI@ Childrens (TRIC) are dedicated state-of-the-art facilities for conducting patient-centric, investigator-led and industry-sponsored clinical trials.

The TRI CRF specialises in adult clinical research. Situated within the Research wing of the Princess Alexandra Hospital, a major tertiary referral hospital in Southeast Queensland, the CRF was established by TRI and is operated on behalf of TRI through a service level agreement by Metro South Hospital and Health Service. The CRF has an excellent track record in conducting Phase 1-3 high quality clinical research trials across a wide variety of therapeutic areas.

TRIC, which is located at the Centre for Children's Health Research next to the Queensland Children's Hospital – specialises in paediatric research.

The CRF and TRIC's proximity to major hospitals offers seamless integration of research and commercial trials in both adults and children. Both facilities offer a range of specialised resources and expertise, including an on-site Nurse Manager to manage day-to-day operations and provide support and assistance with clinical trial activities.

Type of Studies

- Investigation of disease mechanisms
- Genetic and diagnostic evaluations
- Exercise testing and movement studies

Skin imaging

- Early-phase clinical trials
- Interventional research programs and clinical trials for all phases of new medicines and medical devices

TRI'S CLINICAL TRIAL FACILITIES

Clinical Research Facility (CRF)

Positioned within Brisbane's Princess Alexandra Hospital's campus, the CRF is equipped to support multi-phase adult clinical trials.

GCP Aligned Facilities include:

- Four-bed ward and short-stay rooms
- Phlebotomy facilities
- Clinical nurse's station
- Pharmacy storage for investigational product
- Bio-specimen storage
- Exercise gym
- Temperature-controlled rooms
- Vectra imaging system
- Sample processing laboratory
- Office and open plan desks
- Meeting rooms and privacy booths
- Secure file storage
- Fully integrated electronic medical records

TRI@Children's (TRIC)

TRI's paediatric clinical trial facilities are based conveniently at the Brisbane Children's Hospital, with direct access to emergency services.

GCP Aligned Facilities include:

- Medium and large consult rooms
- Observation room (two beds)
- Procedure and examination rooms
- Small interview rooms
- Laboratory (four bench)
- Open plan desks and shared office space
- Telephone booths
- Calm room
- Meeting rooms and privacy booths
- Separate adult and children's waiting rooms

Clinic@TRI / **Translational Trials**

Translational Trials is a team of clinical research professionals at TRI who are dedicated to advancing clinical trials. The team has extensive experience providing clinical trial management and coordination services across multiple phases of clinical research.

The Translational Trials team's purpose is to work with industry, clinical researchers, PIs and site staff to provide quality clinical trial services for investigator-initiated and commercially sponsored clinical trials.

The team supports all stages of clinical trials from feasibility assessment, through start-up, clinical conduct and closeout.

The services offered by the facilities include feasibility assessment, protocol development, Ethics and Governance submissions, budget negotiations and the full conduct of clinical trials by nursing, pharmacy and laboratory staff.

World-first sutureless nerve repair

In conjunction with TRI's Translational Trials Team, and Australian Centre for Complex Integrated Surgical Solutions (ACCISS), the COAPTIUM Connect System Australian trial is underway with procedures performed at both Princess Alexandra Hospital and Gold Coast University Hospital.

PA Hospital Plastic and Reconstructive Surgeon, Dr Michael Wagels (pictured) who performed the first surgery said the technology allows nerve repair to be made without the use of sutures which can negatively impact the nerve.

"Removing the need for sutures allows better regeneration of the nerve, benefiting the patient long term," said Dr Wagels. "I am optimistic this new technology can bring us a step closer to better nerve repair outcomes in the future."

The COAPTIUM Connect Sutureless Nerve Coaptation System, by medical technology company TISSIUM, has been designed for consistent nerve repair, leveraging their unique biopolymer platform.

TRI CEO Professor Scott Bell said the trial underscored the value of collaboration between clinicians and industry, essential in translating research findings into new treatments. In this case, providing a novel surgical option for a challenging medical condition.

Vaxxas children's clinical trial at TRIC

Australian biotech Vaxxas, is pioneering a new approach to vaccine delivery, through its novel skin patch technology covered in thousands of vaccine-coated microprojections. The tiny patch has the potential to replace traditional needle and syringe for routine and pandemic vaccination and could be self-administered or administered by a parent or guardian.

In 2022, the Vaxxas team conducted a clinical trial at TRIC, TRI's clinical research facility at the Queensland Children's Hospital. Using a placebo coated patch, the trial involved 10 children, and 10 parents, and focused on assessing the technology's application in a paediatric setting including how well it was tolerated by children and accepted by parents.

"Having access to TRIC through our TRI affiliation helped us immensely with this clinical trial. The TRI ecosystem means not only do we have access to facilities like CRF and TRIC but we also have access to other researchers and clinicians who can provide their expert advice and support."

Industry@TRI

Incubated
8 Early-stage MTP Companies

Home to
6 Sector Service Providers

250 Industry Employees

TRI is proud to be a catalyst for Queensland's medical research as a leading hub for translational research, novel innovation, commercialisation, and scale-up manufacturing.

Along with researchers and clinicians, TRI houses start-up biomedical technology (biotech) companies that are in their early stages of research and product development, as well as companies that provide support services to the biotech sector.

TRI has created a networked ecosystem that includes researchers, clinicians, consumers, and these biotech companies. This model aims to bolster the biotech sector in its start-up, pre-revenue phase by providing a facilitated platform for companies while they are developing their medical interventions or technologies and conducting early phase clinical studies.

Biotech tenants at TRI have access to world-class facilities including laboratories (wet labs/PC2 labs), cGMP compliant cleanrooms (T3), eight core facilities with specialised equipment and expert advice and support, 24/7 critical systems monitoring and various on-site temperature storage facilities, and access to specialist expertise.

The TRI facility gives these biotech companies time to establish, build, test and develop their products and provides a supportive environment to advance medical discoveries to healthcare solutions.

Additionally, TRI leases a large-scale bio-pharmaceutical manufacturing facility to Patheon, Thermo Fisher Scientific.

Access to these facilities and expertise offers a high value option, unavailable elsewhere in Australia, to growing biotech companies. By filling a recognised gap in infrastructure, expertise and training this will help keep start-ups in Queensland and attract others to the State.

This year saw significant growth in the number of commercial occupants at TRI. We welcomed Infensa Bioscience spun out of a research group at UQ Institute for Molecular Bioscience; TRI cleanrooms continued to be utilised by our largest commercial partner, Vaxxas; and we established our first commercial partner from TRI research, Sicario Therapeutics.

In June, Glenda Colburn was appointed to the new role of Industry Engagement Manager. This position is responsible for expanding on TRI's successful collaborations with industry and continuing to connect industry with researchers and clinicians to improve the translational pathway.

TRI is proud to be home to eight early-stage MTP companies, and six biotech sector service providers.

Early-Stage Companies at TRI

Microbio
MICROBA
vaxxas
Vale
Ocugene
EMVISION
Oroborus
infensa BIOSCIENCE

Biotech Sector service providers at TRI

MTPConnect
THERAPEUTIC INNOVATION AUSTRALIA
BRANDON CAPITAL
National Imaging Facility
360biolabs
Health Translation Queensland



Industry@TRI / **Vaxxas**

Since 2014, the TRI has been home to Australian biotech, Vaxxas, a company which is set to redefine vaccine delivery with its innovative high-density microarray patch (HD-MAP) technology.

The patch is made up of thousands of microprojections a quarter of a millimetre long that are dry coated with a vaccine. When applied to the skin for just seconds, the technology directly deposits the vaccine to the dense population of key immune cells in the skin prompting a more robust and dose-efficient immune response compared to traditional needle-and-syringe delivery.

In 2022 Vaxxas published findings from a pre-clinical trial showing the patch was approximately 11 times more effective at combatting the Omicron COVID-19 variant when compared with the same vaccine administered via a needle.

A placebo paediatric clinical trial at TRIC, TRI's clinical research facility at the Queensland Children's Hospital, was also undertaken.

Phase I clinical trials also commenced for a COVID-19 vaccine patch, marking a significant milestone for the company towards seeking TGA and FDA approvals.

Vaxxas has raised $34 million through an investment round led by OneVentures and UniQuest to progress multiple vaccine programs and received $8.2 million from the Australian government 's Modern Manufacturing Initiative (MMI). The MMI funds will support the installation of specialised infrastructure at the company's new manufacturing facility in Brisbane's Northshore precinct developed with support from the Queensland Government.

"TRI has given us credibility with our industry partners, governments, and international pharma companies that come to visit us from overseas. When they walk into the TRI, all of a sudden our status is lifted, and it goes a long way to us getting the contracts we have working in this environment."

— **Mike Junger, Senior Vice President Advanced Technology Vaxxas**

Industry@TRI / **Microba**

TRI-based Microba Life Sciences (ASX:MAP) is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians and consumers.

In 2022, Microba significantly advanced its therapeutic programs, and its global technology leadership position continued to attract prominent partners across the globe, such as US-based Ginko Bioworks (NYSE:DNA) and International Flavours and Fragrances (NYSE:IFF).

The company has continued to see growing demand for its microbiome testing services, including a strategic partnership with Sonic Healthcare (ASX: SHL) and new partnerships opening up the US and the Middle East for the first time.

Of note, in 2022 Microba Life Science was listed on the ASX after raising $30 million.

"TRI is an amazing facility with core infrastructure that really drives science. One of the biggest advantages for us was the opportunity to have an academic group alongside Microba, and on the same floor, allowing us to have direct interaction.

TRI has that unique triangulation of the hospital and the medical research that's underpinned there, the academic research and the excellence of the universities in this building, but also bringing together multiple innovative biotechnology companies that are translating that research from the bedside into the market. So, it makes sense for us to be here."

—— Dr Luke Reid, Chief Executive Officer, Microba Life Sciences

Industry@TRI /
Brandon Capital

Brandon Capital is a collaboration between medical research institutes, universities, hospitals and government which seeks to identify promising technologies and companies for investment, while also providing a framework for growth and development of the sector.

With over $700 million in funds under management, Brandon Capital invests in companies derived from members, providing venture funding in the form of equity finance. Brandon Capital is a life-science focused investor with 28 active portfolio companies, investing in therapeutics, diagnostics and medical devices.

The Queensland office has been based at TRI since 2019. There are three Brandon Capital portfolio companies, Vaxxas, Kimaritec and Sicario Therapeutics based at TRI. The Queensland team actively meet with researchers, technology transfer groups and companies at TRI to explore and review opportunities for investment.

"We chose the Translational Research Institute as the Queensland office for Brandon Capital primarily due to the integrated nature and culture of the Institute towards translational activities. The central location in Brisbane's Knowledge Corridor was also important."

Dr Goslik Schepers,
Senior Investment Manager,
Brandon Capital

Industry@TRI /
Infensa Bioscience

In 2022, TRI welcomed Brisbane-based startup company Infensa Bioscience to its community of commercial incubators. Infensa had secured $23 million to fund clinical trials of a potentially lifesaving therapeutic to treat heart attacks and strokes.

The drug candidate, discovered by a UQ team in the venom of the K'gari funnel-web spider, is designed to prevent the tissue damage caused by heart attack and stroke. Infensa plans to progress this drug candidate (IB001) to clinical trials after licensing the intellectual property from UniQuest.

Infensa Bioscience plans to start Phase I clinical trials for treatment of severe heart attacks next year.

"It's great to join the TRI community. With the support and collaborative environment provided by TRI, we are confident Infensa Bioscience can navigate the path to clinical trials and contribute to addressing the largest global health challenges of heart attack and stroke"

Infensa Bioscience CEO
Associate Professor Mark Smythe

TM@TRI

TRI AND TM@TRI WILL:

Service the biomedical sciences ecosystem

Encourage innovation through good science and good business

Strengthen and protect Australia's global position in the biomedical sciences

Accelerate the commercialisation of promising treatments, therapies and cures to improve patient care

Create jobs and drive economic and STEM workforce development.

Translational Manufacturing at TRI (TM@TRI) will be the first facility of its kind in Australia to support mid-stage biotech companies as they mature, expand and scale-up product manufacturing.

TM@TRI is critical to allow biotech companies to remain based in Australia and to retain home-grown innovations and discoveries on shore. It will provide infrastructure, support and services at a greater scale to allow the start-up companies born from local research discoveries to expand into scale-up spaces. As such, TM@TRI will accommodate start-ups, scale-ups and other associated players in the biomedical research ecosystem.

TM@TRI is proudly funded by the Queensland Government and TRI. In 2022, the Queensland Government increased its support to up to $60 million, to bolster a $20 million investment from TRI's shareholders.

In a media statement announcing the additional investment in June 2022, Queensland's Deputy Premier and Minister for State Development, Infrastructure, Local Government and Planning, Steven Miles, said TM@TRI would help keep MedTech start-up companies in Australia.

"At the moment, a lot of our small and medium-sized MedTech start-ups are forced to move offshore because they can't manufacture their medical products at a large enough scale to support Phase II and III clinical trials here in Australia," Deputy Premier Miles said.

"This facility will provide the infrastructure they need to scale up to full production to support late-stage clinical trials and will therefore help keep our innovative start-ups – and the high-value jobs they create – here in Queensland."

Treasurer and Minister for Trade and Investment, Cameron Dick, said Queensland researchers had



been behind some of Australia's most important medical breakthroughs.

"Look no further than TRI's own Professor Ian Frazer and the lives he has changed around the world with Gardasil®," the Treasurer said.

"Building on Queensland's strengths from early-stage research to our internationally recognised clinical trials capabilities, TM@TRI will support Queensland's growing pipeline of start-ups."

"We are providing an avenue for the pipeline of innovative biomedical products in development to be manufactured locally, retaining local companies and talent as well as attracting new companies looking to set up in the Asia-Pacific region."

KEY FACTS AT A GLANCE

2000 jobs will be created - 1500 construction + 500 highly skilled/STEM roles

Cost Benefit Ratio: $1 invested in TM@TRI returns $1.51 in economic benefit back to Australians

Shovel Ready – Q3 2023 early construction works, Q3 2025 opening

TM@TRI will be Australia's only facility where companies can perform their own product manufacturing in regulatory-compliant cleanrooms

It will enable TRI to expand the open access to current Good Manufacturing Practice (cGMP) training upskilling Australia's workforce in the methods, facilities and controls used in manufacturing

Building a OneTRI Culture

Collaboration is the lifeblood of translational medical research – we need laboratory scientists, clinicians and industry all working together. To bridge the gap between scientific discovery and tangible clinical applications, the synergy of minds from various disciplines is essential. It is through collaboration that we leverage diverse expertise, share insights, and break down silos, accelerating the journey from the lab bench to the patient's bedside, and back again.

TRI is built on a strong foundation of collaboration. For this reason, in 2022 we continued to invest heavily in building a OneTRI culture. Over the year TRI delivered a coordinated program of OneTRI events that brought together the whole building to create a shared purpose and a sense of community.

The pandemic remained both a challenge and an opportunity throughout 2022. TRI's ELT and our partner leaders working together to respond to several COVID-associated lockdowns, along with close collaboration with Metro South and PAH administration regarding bed management and short-term access to the Clinical Research Facility for medical oncology and surgical day patients.

When the Board mandated a COVID-19 vaccine requirement for all the TRI community, several high-level discussions with the Chief Medical Officer culminated in TRI's inclusion under the Vaccine Mandate Direction by the CHO. This was implemented quickly and effectively with proof of COVID-19 vaccination (or an exemption) a requirement to enter TRI facilities.

During the past 12 months 20 TRI-wide communiques have been circulated in relation to the pandemic. At all times the focus was placed on developing a consistent and concise communications plan; supporting the TRI community to work from home where they were able; and creating provision for authorisation to enter TRI for only those undertaking critical research or supporting researchers with their critical research.

Despite these ongoing COVID complications, many key initiatives were able to progress in 2022, including new grant programs and funding opportunities; a wide program of online and in-person events, including three Town Hall meetings; important initiatives like our Reconciliation Action Plan and Sexual Harassment Awareness and Prevention Week; plus moments to enhance workplace wellbeing, connectedness and celebration, such as the annual OneTRI Awards.

Grants and Funding

LINC GRANT PROGRAM

The LINC (Leading Innovations through New Collaborations) program was co-developed by TRI, Metro South Health and Mater Research in 2021. The program provides dedicated seed funding for new research collaborations between early to mid-career researchers based at TRI and early to mid-career clinicians based at Metro South, Mater or the Queensland Children's Hospital. This culminated in a showcase event with 12 researchers and clinicians presenting research questions and clinical dilemmas.

In 2022, $350,000 was provided for seven new LINC grants, each receiving $50,000. The successful grant applicants include early career clinicians from fields such as respiratory medicine, dermatology, psychiatry, gastroenterology, neurology, obstetrics and gynaecology as well as orthopaedic and neurosurgery coming together with EMCR researchers from all TRI partners.

TRI-CSIRO GRANT SCHEME

In 2022, TRI and the CSIRO Australian e-Health Research Centre announced they would jointly offer three $100,000 grants for collaborative research projects aimed at solving a healthcare challenge.

All grant applications had to involve a TRI-based researcher, a CSIRO Australian e-Health Research Centre scientist, and a TRI partner clinician (from either Metro South Health, Mater or Children's Health Queensland).

TRI-based investigators Professor Elizabeth Powell (UQ/MSH), Professor Erik Thompson (QUT) and Eamonn McKenna (QUT) along with their CSIRO AEHRC/MSH collaborators were awarded grants to fast-track digital healthcare solutions using cutting-edge technology to improve the diagnosis, treatment, prevention of liver disease, breast cancer and diabetes-related foot ulcers, respectively.

TRI FOUNDATION RESEARCH GRANTS

In August 2022, the TRI Foundation funded two grant schemes aimed at TRI-based EMCRs and affiliated clinicians. One $3,000 grant was awarded for breast cancer research from funds raised through the TRI Foundation Breast Cancer Appeal, and one $10,000 grant was awarded for research into kidney failure/dialysis, from funds provided by a corporate donation.

Building a OneTRI Culture/
Event Highlights

The easing of pandemic restrictions saw a welcome return to face-to-face seminars. As well as a full schedule of Research Translation Seminars, the Game Changer series and Director's Choice series continued to attract high-calibre and high-profile speakers to TRI to address important issues facing the sector.

Following the successful launch of the Cores Conference in 2021 at TRI in partnership with QIMR-Berghofer, the conference will be held again in 2023 at QIMR. This collaboration fills a gap in the professional development opportunities available to Core Facilities staff and attracts delegates state-wide and nationally.

TRI's Translate 2022 Conference was conceived to further foster collaboration between researchers, clinicians and industry.

A partner and industry representative steering committee was assembled to plan for the two-day industry-facing conference to be held at TRI. Members of the committee included representatives from the Chief Entrepreneur's Office, Health Translation Queensland, Thermo Fisher, UQ's Australian Institute for Bioengineering and Nanotechnology and Life Sciences Queensland, along with TRI Corporate staff.

The conference was designed to support linkages between researchers, clinicians and start-up SME MedTech Industry. The conference aimed to enhance clinical trials capability, especially for investigator-initiated and early phase clinical trials. It further enhanced clinician, researcher and industry links with the Translational Trials team at TRI and the clinical research facilities at Metro South Health (Princess Alexandra Hospital) and Children's Health Queensland.

TRI hosted the highly successful Translate 2022 in October with significant sponsorship support from industry and over 300 registrations from 113 organisations.

FEATURED EVENT : TRANSLATE CONFERENCE 2022 EVENT AT A GLANCE

2 DAY CONFERENCE

34 Expert Speakers

250 In-Person Delegates

53 Online Delegates

113 Organisations Represented

Building a OneTRI Culture/ **Reconciliation Week**

In 2022 a Steering Committee was formed to start the important journey of developing a Reconciliation Action Plan (RAP).

The RAP program advances reconciliation by supporting organisations to develop respectful relationships and create meaningful opportunities with Aboriginal and Torres Strait Islander people.

TRI is grateful for the valuable input of Tagai Management Consultants' Murray Saylor, and Elders Aunty Beryl Meiklejohn, who quietly yet firmly kept our REFLECT Rap process moving forward across 2022, and Uncle Charles Passi, who contributed great insight to our early planning.

Developing TRI's RAP was driven within our OneTRI Community by key individuals including: Paul Clarke, Helen Benham, Scott Bell, Hayden Crowley, Natasha Jansz, Jeremy Keevers, Celestine Fisher, Samantha MacDonald, Shivashanker (Shiv) Nagaraj, Siobhan Barry, Jennifer Skinner, Charlotte Vivian and our RAP champions Kirsten Kiel-Chisholm and Ryan Galea.

The group also commissioned Wakka Wakka man David Williams, of Gilimbaa, to create a RAP artwork unique to TRI. Called 'Let their voices guide us and connect us to a healthier future', this artwork tells the story of TRI's reconciliation journey. A story that started with collaboration. A story built on the strength of its relationships. A story whose future depends on connection.

A Town Hall was held to involve the TRI community in the RAP initiative. Presentations were made by Aunty Beryl Meiklejohn (RAP Committee member and proud Quandamooka woman), Joanne Esiram (MetroSouth), Dr Natasha Jansz (Mater Research) and Professor James Ward (UQ) who addressed what reconciliation means to them.

This year, OneTRI held its inaugural Reconciliation Week event. Over 200 people attended the morning tea where CEO Professor Scott Bell highlighted that reconciliation is "everyone's business" and in keeping with the theme of Reconciliation Week, challenged the TRI community to ***Be Brave and Make Change*** by tackling the unfinished business of reconciliation for the benefit of all Australians.

In late 2022 TRI lodged its first RAP, awaiting official endorsement from Reconciliation Australia.

Building a OneTRI Culture/

Sexual Harassment and Awareness Prevention Week

The OneTRI-led Sexual Harassment and Awareness Prevention (SHAP) Week had excellent engagement across all partners including TRI Corporate. A diverse week-long program, it included a keynote seminar focussing on respect within the workplace as being core to developing a culture of prevention. The second keynote address concentrated on providing signs to recognising sexual harassment and then engaged with a multi-partner four-person panel made up of several of the 20 OneTRI community members who completed the First Responder training during the week.

The First Responder group has created a network of first responders who meet regularly for ongoing education, support and sharing their experiences. Importantly members of the group are visible at events and promoted around the building. Ethical bystander training was also held for TRI corporate and partners to build their skills, knowledge and confidence on the safest ways to intervene if they witness an event that concerns them.

In October 2022, a one-day Spotlight on Sexual Harassment and Prevention symposium was also held at TRI with four exceptional speakers – QUT's Dr Christina Malatzky, UQ's Professor Ethan Scott, Paralympian Karni Liddell and Brisbane Lions AFLW CEO Breeanna Brock.

Building a OneTRI Culture/
Wellbeing Activities

To fully embrace the TRI goal of collaboration under the new Strategic Plan, specifically "promoting a 'One-TRI' culture and providing a workplace that values safety, diversity, inclusion, health and wellbeing", the TRI Corporate-led Wellbeing Committee evolved to become Wellbeing@OneTRI.

Partner representation was welcomed to the Committee to ensure a whole community approach to wellness activities and to avoid duplication of events. Throughout 2022 the focus was on promoting self-care and resiliency; diversity and inclusion; domestic violence awareness; as well as physical and mental health initiatives.

Building a OneTRI Culture/
EMCRs

During 2022 TRI built on its continuing focus on the EMCRs in the OneTRI community. Key initiatives included the establishment of an EMCRs monthly newsletter within TRI; the institution of a regular morning tea EMCRs forum allowing the group to meet; network; and experience talks by senior academics such as UQ's Professor Al McEwan and QUT's Professor Erik Thompson. The EMCRs have also been provided with opportunities for the coordination and chairing of Research Translation Seminars. Many of the ideas implemented across 2022 came from the feedback provided through a TRI EMCR survey. An EMCR Committee has also been formed to shape and advance future initiatives.

Building a OneTRI Culture/
OneTRI Awards

Each year we celebrate those who have consistently exemplified the TRI values and contributed to a OneTRI culture. This year the recipients were:

- The EMCR committee including Lisa Philp, Mark Adams, Erin McMenamin, Giorgia Mori, Kavita Bisht, Lauren Aoude, Ra'eesa Doola, Ran Wang, Sonia Henriques, Julia Renaud and Benedette Watson
- Ryan Galea for showing leadership, integrity, collaboration and excellence in his work on the Reconciliation Action Plan
- Lisa Philp as for being an excellent ambassador for TRI, fostering an integrated and inclusive community across the research partners, and striving for research excellence
- Maria Wojciechowski for building relationships across TRI, and encouraging a culture of partnership and collaboration
- The first five graduates of TRI's Translational Pathways program: Mark Adams, Kristen Radford, Jenni Gunter, Arutha Kulasinghe and Aideen McInerney Leo
- Kristen Radford for establishing the only humanised mouse facility in Australia and sharing research innovations generously to benefit science as a whole
- Mark Adams for being a highly committed leader who regularly contributes to TRI partner committees, industry, community, EMCR and peer mentoring engagement initiatives

The Awards Ceremony was followed by the TRI End of Year Building Celebration which welcomed close to 300 attendees from across the TRI community including all TRI's partners and commercial partners. The OneTRI awards will continue to feature as an annual TRI event.

TRI Foundation

The TRI Foundation seeks to develop sponsorship programs, internships, scholarships, fundraising events and commercial partnerships to support medical research at TRI.

The Foundation assists our partner institutes with fundraising for patient research and support services and contributes to the training and development of early-career researchers and students at TRI.

In 2022, funding was received from a range of sources including corporate donations, fundraising events, TRI staff workplace giving, and bequests.

2022 EMCR Research Grants

In August 2022, TRI launched two grant schemes aimed at TRI-based EMCRs and affiliated clinicians. Two grants of $3,000 each are available for breast cancer research. The funds being distributed were raised through a Breast Cancer Appeal TRI established in 2019. QUT's Professor Erik Thompson organised a Breast Cancer Awareness Symposium in October, which involved fundraising for the Breast Cancer Appeal.

A $10,000 grant was available for research into kidney failure/dialysis from a $10,000 donation from YHC Lawyers.

The recipients were:

- Dr Robert Ellis ($10,000) – "Differentiating acute rejection from other causes of delayed graft function after kidney transplantation using magnetic resonance imaging and spectroscopy";

- Dr Sugandha Bhatia ($3000) – "Investigating the landscape of chromosomal aberrations in breast cancer cell models."

Travel Grants

In November 2022, the TRI Foundation launched a travel grant scheme for students and early-career researchers based at TRI. Travel sponsorships of up to $1,000 each were available to help them present their research at an international conference, or to attend a conference within Australia.

The TRI Foundation received 15 strong applications, ultimately awarding four scholarships. Chair of TRI Foundation Board, Emeritus Professor Ian Frazer presented the grants to the successful applicants at a small ceremony at TRI on 15 December 2022 to the following recipients:

- Dr Irina Buckle – attending the 19th Immunology of Diabetes Society Congress in Paris and planning a visit to University of Exeter Medical School;
- Ms Ellie Maas – attending the American Society of Human Genetics Conference in Washington DC, and a visit to Memorial Sloan Kettering Cancer Centre in New York;
- Ms Natasha Jansz attending the Lorne Genome Conference in Victoria, and visiting the Doherty Institute in Melbourne; and
- Ms Rachel Rollo – attending the Tuberculosis Drug Discovery and Development Conference in Castelldefels, Spain, and visiting a number of institutes in Germany, the Netherlands and the UK.

Bequests and memorials

The TRI Foundation was honoured to have received several generous bequests in 2022 which will be used to facilitate and promote ground-breaking research at TRI.

By leaving a legacy, donors can help to fund a research program which could lead to a treatment or cure, sponsor a PhD student as they start their career in health science, or purchase new equipment to get an important project off the ground.

TRI Foundation can work with donors to structure specific programs, ensuring funds bequeathed are utilised to create a lasting legacy. All donations to TRI Foundation are tax deductible.

Governance
TRI BOARD

TRI is governed by a Board of Directors. Led by the Independent Chair, Emeritus Professor David Siddle, and comprised of the following nominee directors from each of the shareholders:

- **Professor Aidan Byrne (The University of Queensland)**
- **Emeritus Professor Carol Dickenson (Queensland University of Technology)**
- **Mr Jim Walker (Mater Research)**
- **Dr Peter Bristow until 7 October 2022 (Queensland Health)**
- **Ms Colleen Jen from 7 October 2022 (Queensland Health)**

The Board is supported by the Company Secretary, Ms Kirsten Kiel-Chisholm.

Back Row Left to Right; **Ms Kirsten Kiel Chisholm, Professor Scott Bell, Professor Aidan Byrne.**
Front Row Left to Right; **Emeritus Professor Carol Dickenson, Emeritus Professor David Siddle and Ms Colleen Jen.**

CHAIR

Emeritus Professor David Siddle,

BA (Hons), PhD, FASSA

David Siddle obtained his PhD from the University of Queensland in 1971. As an academic psychologist, he worked in universities in England, Canada and Australia. After appointments at Macquarie University, University of Tasmania, and the University of Queensland, he was appointed as Pro-Vice-Chancellor (Research) at the University of Sydney in 1997. He served as Deputy Vice-Chancellor (Research) at the University of Queensland from 2001 to 2009 where he was responsible for the development and implementation of policy designed to enhance the university's performance in research and research training. He was Chair of the Humanities and Social Sciences Panel of the Australian Research Council in 1993 and 1994 and after retirement, served on the Australian Research Council's Advisory Council. He has served as a Board member for many Cooperative Research Centres, was a Director of the Australian Synchrotron Company and from 2011 to 2014, served as a member of the Higher Education Standards Panel. Until 2017, he was Chair of Brisbane Diamantina Health Partners.

UQ NOMINEE

Professor Aidan Byrne

BSc MSc PhD

Provost and Senior Vice-President, The University of Queensland

Professor Aidan Byrne commenced as the Provost and Senior Vice-President of The University of Queensland on 4 October 2016.

Prior to this appointment Professor Byrne was the Chief Executive Officer (CEO) of the Australian Research Council (2012-2016), a position in which he delivered increased knowledge and innovation through managing funding schemes, measuring research excellence and providing policy advice to Government.

Before that, he was Dean of Science and Director of the Australian National University (ANU) College of Physical and Mathematical Sciences (2008-2012). He was also Head of the ANU Department of Physics (2003-2007).

Professor Byrne completed a Bachelor of Science and a Master of Science (First Class Hons) in physics at the University of Auckland in New Zealand and has a PhD in nuclear physics from ANU. He was a National Research Fellow at the University of Melbourne (1985-1986) and a von Humboldt fellow at the University of Bonn, Germany (1986-1989). In 1991 Professor Byrne returned to ANU as a Research Fellow.

His research interests involve the use of gamma-rays as probes to determine the structure of heavy nuclei, and the examination of the atomic level structure of materials (especially semiconductors). He has published more than 200 papers.

In 2012 Professor Byrne was awarded the ANU Peter Baume Award for eminent achievement and merit of the highest order.

Professor Byrne is a member of the MBIE Science Board (New Zealand) and the National Research Foundational Scientific Advisory Board (Singapore). He is also a fellow of the Australian Institute of Physics.

He was previously a member of the National Science, Technology and Research Committee, Prime Minister's Science, Engineering and Innovation Council (PMSEIC), Defence Intelligence Organisation Scientific Advisory Group (2007-2008), the ARCom Expert Advisory Group and a member of the Australian Academy of Science Committee for Physics (2005).

QUT NOMINEE

Emeritus Professor Carol Dickenson

AM B Bus (Mgt) QIT PhD UQ

Queensland University of Technology

Following a 30-year career at QUT, Emeritus Professor Carol Dickenson AM retired at the end of 2019. Of these 30 years, 20 were in leadership and management positions including Provost, Senior Deputy Vice Chancellor and University Registrar. Her career trajectory was different to many, moving between academic and professional senior roles, resulting in leadership over large parts of the university during times of significant growth in terms of size and outcomes.

Since retiring from QUT, she has taken on the role of President of The Women's College Council within The University of Queensland, a role equivalent to Chair of the Board. Emeritus Professor Dickenson has also remained on the TRI Board as the QUT nominee and undertaken consultancy work for a number of higher education institutions in Australia. She has also mentored/coached a number of senior executives.

MATER RESEARCH NOMINEE

Mr Jim Walker AM

Independent Director

Jim Walker is a senior executive with significant corporate leadership and management experience, both nationally and globally.

He has held senior executive positions with United Technologies, Rockwell Collins and Boeing, leading and building businesses across Australia and the Asia Pacific. He also has significant board and governance experience, both in Australia and Asia.

He is a graduate of the Australian Institute of Company Directors and has director experience with listed company, joint venture, not-for-profit and advisory boards.

METRO SOUTH HEALTH NOMINEE (UNTIL 7 OCTOBER 2022)

Dr Peter Bristow

MBBS GradCertMgt GAICD FRACP FCICM FRACMA

Chief Executive, Metro South Health

Prior to commencing as the Chief Executive Officer for Metro South Health, Dr Bristow was the CEO of Health Support Queensland where he was responsible for a wide range of diagnostic, scientific, clinical and payroll services to enable the delivery of frontline healthcare across Queensland.

Dr Bristow has held the positions of CEO of the Darling Downs Hospital and Health Service and CEO of the Townsville Hospital and Health Service. From 2015 until 2017, he was Chair of the Queensland Health Service Chief Executive Forum and has also previously worked as Director of Intensive Care and Executive Director of Medical Services at Toowoomba Hospital.

Dr Bristow trained and worked as an intensive care physician at Liverpool Hospital in Sydney before moving to the Alfred Hospital in Melbourne. He is a Fellow of the Royal Australasian College of Physicians; a Fellow of the College of Intensive Care Medicine; a Fellow of the Australian and New Zealand College of Medical Administrators; and a Graduate of the Australian Institute of Company Directors. Dr Bristow also holds a Graduate Certificate in Management.

MSH NOMINEE FROM 8 OCTOBER 2022

Ms Colleen Jen

BN MCCN GD MAICD

Deputy Director-General Clinical Planning and Service Strategy, Queensland Health

Colleen Jen is an experienced executive and health professional with more than 38 years working in the health sector. Colleen is a Registered Nurse and has extensive experience in health service strategy and planning, as well as leading strategic policy, Aboriginal and Torres Strait Islander health and infrastructure planning teams in Queensland Health.

Colleen has recently been appointed as the Deputy Director-General Clinical Planning and Service Strategy. Clinical Planning and Service Strategy (CPSS) is a newly created division in Queensland Health responsible for delivering clinical service strategy and planning, workforce strategy and planning and leadership, mental health strategy and planning and precision medicine and research functions to improve health services available to the Queensland community, optimise health gains, reduce inequalities, and maximise the efficiency and effectiveness of the health system.

Previously Colleen has worked as a Principal for Deloitte Health Advisory, Executive Director, Health Service Strategy and Planning Metro North Hospital and Health Service and Senior Director, Health Service Planning Department of Health.

Governance

EXECUTIVE LEADERSHIP TEAM

CHIEF EXECUTIVE OFFICER

Professor Scott Bell

MBBS MD FRACP FThorSoc GAICD

Professor Bell is a leading clinician and researcher in Cystic Fibrosis (CF). As well as being TRI's CEO, he holds an appointment as a Senior Thoracic Physician at the Prince Charles Hospital. He also leads a lung bacteria group at UQ's Child Health Research Centre. Prior to his appointment as TRI's CEO, Professor Bell was the Executive Director of Research at Metro North Hospital and Health Service. He was the Editor-in-Chief of the Journal of Cystic Fibrosis from 2013 until 2020.

He recently co-led the development of a new global blueprint for the care of people with CF. His work will help the 3,500 Australians with the incurable genetic disorder to live decades longer. He has more than 290 peer-reviewed publications and has received more than $24 million in grant support over the past 10 years.

DIRECTOR, BUILDING OPERATIONS

Michelle Richards

BSc PGradDipCM MBA GAICD

Michelle commenced as Director of Building Operations at TRI in 2016, after 4 years establishing key operational functions during the development of TRI. In her role, she oversees TRI's largest business unit, which incorporates Building Services, Core Facilities, Workplace Health and Safety, Scientific Services, and Central Stores and Sterilisation. Michelle is also responsible for the start-up industry presence at TRI, as well as the cleanrooms that provide manufacturing capabilities to the institute's commercial occupants.

Prior to joining TRI, she worked in medical research in Australia and the United Kingdom for more than 10 years, gaining expertise in areas including molecular biology, immunology, developmental biology and clinical trials. Michelle is a Graduate of the Australian Institute of Company Directors.

DIRECTOR, LEGAL SERVICES

Kirsten Kiel-Chisholm

LLB (Hons I) BIntBus GradDipAppCorpGov FGIA ACC-ICC

Kirsten commenced at TRI in July 2009 and is an experienced General Counsel and Company Secretary. As Director of Legal Services, Kirsten is responsible for managing the Institute's legal requirements and providing legal advice to the Board and management across a range of areas. Kirsten also oversees Human Resources, Compliance and Internal Audit for the Institute.

Kirsten previously worked as General Counsel and Company Secretary for the CRC for Sustainable Tourism. Prior to that she was a corporate lawyer in private practice in both Australia and the United States and co-authored 3 publications on compliance with ASX and APRA corporate governance requirements.

DIRECTOR, FINANCE

Sue Davis

AssocDipBus BBus (Mgt) CPA

Sue joined TRI in July 2020 as Finance Director with strategic oversight of Finance, IT and Quality Management. Prior to joining TRI Sue held senior finance and operational roles with TAFE Queensland, Bond University and Infinite Aged Care Group.

DIRECTOR, COMMUNICATIONS AND MARKETING

Siobhan Barry

BA (Hons I) BJ

Siobhan joined TRI in September 2021 after years working in communications management roles in the medical research sector. She started her career as a journalist with the Australian Broadcasting Corporation, and prior to joining TRI, Siobhan was the Manager of Media, Government and Community Relations at QIMR Berghofer Medical Research Institute. Siobhan is experienced in corporate and strategic communications, media and government relations, community and stakeholder engagement, and issues and crisis management.

DIRECTOR, CLINICAL TRANSLATION

Associate Professor Helen Benham

MBBS (Hons) BASc (Podiatry) PhD FRACP GAICD

Helen is an experienced Rheumatologist who divides her time between clinical practice at the PA Hospital and translational research into rheumatic diseases. She is an Associate Professor with UQ and a previous NHMRC Translating Research into Practice (TRIP) Fellow.

Helen has experience across the research spectrum, including in basic science, clinical trials and applying the principles of implementation science to her clinical field. Helen is a Director of the Board of Metro South Health and was previously Broad Director of the Princess Alexandra Hospital Research Foundation. She is currently the Chair of Arthritis Queensland.

DIRECTOR, IMAGING INFRASTRUCTURE

Professor Graham Galloway

BSc (Hons) PhD GradCertCompSci

Graham is a former CEO of the National Imaging Facility. He is seconded from UQ to TRI as the Director, Imaging Infrastructure. He is also the Academic Lead for the Preclinical Imaging Core Facility at TRI. Graham's research is defined by finding innovate solutions to novel problems by breaking new ground, and by advancing research using magnetic resonance.

DIRECTOR – ICT

Raj Davio

Bachelor of Science in Computing Science, Diploma of IT Professional Practice (UTS), Master of Business in IT Management (UTS).

Raj initially joined TRI in 2021 in a consulting capacity with responsibility for reviewing the Institute's ICT systems and developing a new technology strategy and governance model. In November 2022, he was formally appointed TRI's inaugural Director of ICT, with responsibility for strategic leadership of technology across the Institute. Prior to joining TRI, Raj consulted for TAFE Queensland as the Executive Director of Strategic Transformation, and before that he was the Director of IT Services at Bond University. Raj is currently on the board of a not-for-profit organisation.

Governance

SHARED LEADERSHIP COMMITTEE

The Shared Leadership Committee (SLC) is chaired by the TRI CEO and is comprised of the most senior member of each of TRI's partners. The SLC is a source of advice to the TRI CEO; a forum for planning collaborative activities; and, in some cases, a decision-making body, except for those matters that are the responsibility of the ELT.

MATER RESEARCH

Professor Maher Gandhi

MBChB PhD FRCP (UK) FRCPath (UK) FRACP

Maher is the Executive Director and Director of Clinical Research at Mater Research, and the Group Leader of Mater's Blood Cancer Research Group. He is also a pre-eminent Senior Staff Haematologist at the Princess Alexandra Hospital. As the Director of Clinical Research, Maher's role is to set strategy and to create a clinical research program that influences future national and international health policy and practice through the full integration of Mater Research with clinical care. Whilst centred on Mater Research, the role also has close involvement with Mater Health, Mater Education and the Mater Foundation.

METRO SOUTH RESEARCH

Professor John Upham

MBBS (Hons) FRACP PhD FThorSoc GAICD

John is the Executive Director, Metro South Health Research. He is also a Respiratory Physician and clinician scientist with interests in immune dysfunction in lung diseases, vaccination and innovative approaches to improving patient care. After completing clinical training in Brisbane, John undertook research training in Western Australia and Canada. He currently holds appointments with the Princess Alexandra Hospital and The University of Queensland. John is the President of the Thoracic Society of Australia and New Zealand.

QUT

Distinguished Professor Patsy Yates

AM PhD RN FACN FAAN

Patsy is the Executive Dean of QUT's Faculty of Health and a Co-Director of the university's Centre for Healthcare Transformation. A Registered Nurse, Patsy has extensive experience as a leader in education and research in the health sector. She leads a large competitively funded research program and also holds visiting appointments at the Royal Brisbane and Women's Hospital and the Princess Alexandra Hospital. Patsy is the Director of Queensland Health's state-wide Centre for Palliative Care Research and Education. She is also a Senior Fellow at the University of Pennsylvania and is the President of the International Society of Nurses in Cancer Care.

UQ

Professor Paul Clarke

PhD FRSB

Paul is Director of The University of Queensland Frazer Institute (UQFI), a leading medical research centre that focuses on cancer, immunology and the genetic basis of disease. UQFI forms a major part of the TRI. Paul joined UQ in 2017 from the University of Dundee in Scotland. He previously held research fellowships at the University of Manchester in England, and the European Molecular Biology Laboratory in Heidelberg, Germany. His current research interests are the molecular mechanisms of cell division, chromosome instability and mitotic cell death. He also studies cellular responses to anti-cancer drugs.

Governance
TRI FOUNDATION BOARD

Emeritus Professor Ian Frazer
BOARD CHAIR

Emeritus Professor Ian Frazer continues to work to raise awareness and funds for medical research as Chair of the TRI Foundation Board. He is also Chair of the Advisory Board for the Medical Research Future Fund and President of the Australian Academy of Health and Medical Science. Professor Frazer's TRI-based research at UQFI included the development of a vaccine for the herpes simplex virus (HSV) and immunotherapies for head and neck cancers.

Internationally renowned for the co-creation of the technology for the cervical cancer vaccines, in 2006, Professor Frazer was named Australian of the Year. As the founding Chief Executive Officer and Director of Research for TRI (2011-2015) Professor Frazer led the development of our world leading biomedical research facility focused on translating scientific knowledge into practical benefits for the community.

Dominic McGann
BOARD DIRECTOR

Dominic McGann is a Partner of McCullough Robertson, a leading Australian law firm. Prior to joining the firm in 1996, Mr McGann held prominent positions with the Queensland Government for seven years and is one of only a few lawyers with a combination of significant senior government experience as well as private practice experience. Mr McGann's extensive experience in communicating and negotiating with indigenous communities, positions him as one of Australian's leading experts in this field.

McGann is also a Director of McCullough Robertson Foundation, Chair of Climate-KIC Australia Limited, Co-Chair of Carumba Institute Advisory Board at QUT, Director of Queensland Music Festival Limited, Director of Frazer Family Foundation and a Member on the Council of QUT.

Craig Casagrande
BOARD DIRECTOR
(FROM 23 AUGUST 2022)

Mr Craig Casagrande is a CFO Advisory Partner and the Brisbane Advisory Lead Partner of BDO, a leading audit, accounting and consulting firm.

With a career spanning more than two decades, Mr Casagrande's expertise lies in advising boards, committees and executives, offering support and guidance in various facets of finance and corporate operations.

Mr Casagrande's portfolio encompasses a diverse range of industries across both the public and private sector, and he has a specialisation in the establishment of corporate and finance functions for infrastructure and major projects.

Dr David Watson
BOARD DIRECTOR
(Until 13 October 2022)

Dr David Watson held the position of Chair of TRI Board from 2009-2017. He has a PhD in accounting from Ohio State University and has previously worked as Associate Professor at the University of Illinois Urbana-Champaign, Professor of Accounting and Business Finance at the University of Queensland 1978-89, Head of the Department of Commerce 1978-82, and twice Dean of the Faculty of Commerce and Economics.

In 2004, Dr Watson was appointed a Commissioner for the Commission of Enquiry into the Integrity Management Systems in the Queensland Racing Industry. Dr Watson is Deputy Chair of the Board of the Queensland Competition Authority and member of the Board of Directors of Tatts Group Limited. He is also on the board of the Accounting Hall of Fame (USA).

Dr Watson has also been a non-executive Director of Sun Retail Pty Ltd, Stanwell Corporation Limited and Sun Gas Retail Pty Ltd. Dr Watson is a Fellow of CPA Australia and a Fellow of the Institute of Chartered Accountants.

Appendix

2022 TRI Partner Group Leaders

Appendix/

Mater Research

TITLE	FIRST NAME	SURNAME	POSITION
Associate Professor	Jakob (Jake)	Begun	Group Leader, Inflammatory Bowel Diseases (IBD) Director, Gastroenterology, Mater Hospital
Professor	Vicki	Clifton	NHMRC Senior Research Fellow Group Leader, Pregnancy and Development
Associate Professor	Paul	Dawson	Mater Foundation Principal Research Fellow Group Leader, Neurodevelopmental Research Head (Education), Mater Research MRI-UQ Director, Higher Degree Research
Dr	Adam	Ewing	Senior Research Fellow Group Leader, Translational Bioinformatics
Professor	Geoffrey	Faulkner	Professor in Neuroscience, Queensland Brain Institute and Mater Research Group Leader, Genome Plasticity and Disease
Professor	Josephine	Forbes	Program Leader, Chronic and Integrated Care Group Leader, Therapies for Diabetes
Professor	Brian	Gabrielli	Professorial Research Fellow Group Leader, Smiling for Smiddy Cell Cycle Research
Professor	Maher	Gandhi	Executive Director and Director, Clinical Research Group Leader, Blood Cancer Research Pre-eminent Senior Staff Haematologist, Princess Alexandra Hospital
Associate Professor	Jake	Gratten	Principal Research Fellow Group Leader, Cognitive Health Genomics
Associate Professor	Sumaira	Hasnain	NHMRC Career Development Fellow and Senior Research Fellow Group Leader, Immunopathology
Professor	John	Hooper	Mater Foundation Fellow and Senior Research Fellow Group Leader, Cancer Cell Biology
Professor	David	Hume	Professorial Research Fellow Group Co-leader, Macrophage Biology
Dr	Dhanisha	Jhaveri	Senior Research Fellow Mater Research and Queensland Brain Institute Program Leader, Neuroscience; Group Leader, Neural Stem Cell Biology Research
Professor	Jean-Pierre	Levesque	Group Leader, Stem Cell Biology Research
Professor	Allison	Pettit	Professor of Medicine Director, Biomedical Research Group Leader, Bones and Immunology
Professor	Kristen	Radford	Principal Research Fellow Co-Leader, Cancer Program Group Leader, Cancer Immunotherapies Research
Dr	Sandra (Sandy)	Richardson	Career Track Fellow Group Leader, Developmental Molecular Genetics
Associate Professor	Katharina	Ronacher	Principal Research Fellow Group Leader, Infection, Immunity and Metabolism Research
Professor	Kim	Summers	Professorial Research Fellow
Associate Professor	Ingrid	Winkler	Senior Research Fellow Group Leader, Stem Cells and Cancer

Appendix/

Queensland University of Technology

TITLE	FIRST NAME	SURNAME	POSITION
Dr	Mark	Adams	Senior Research Fellow Group Leader within the Cancer and Ageing Research Program
Professor	Selena	Bartlett	Professor of Neuroscience Group Leader, Neuroplasticity, Addiction and Neuroscience
Professor	Jyotsna	Batra	Advance Queensland Fellow Group Leader within APCRC-Q
Dr	Nathalie	Bock	Senior Research Fellow Deputy Co-Director, Regenerative Medicine Program Group Leader, Bone and Tumour Bioengineering Research
Dr	Emma	Bolderson	Senior Research Fellow Group Leader, Molecular Biology of Ageing Laboratory Co-founder, Carpe Vitae Pharmaceuticals
Associate Professor	Laura	Bray	ARC Future Fellow Deputy Director, ARC Training Centre for Cell and Tissue Engineering Technologies
Professor	Lisa	Chopin	Group Leader, Gherlin Research
Distinguished Professor Emeritus	Judith	Clements	Member, APCRC-Q
Dr	Laura	Croft	Advance Queensland Industry Research Fellow Group Leader within the Cancer and Ageing Research Program
Adjunct Associate Professor	Michael (Mike)	Doran	NHMRC Research Fellow Program Leader, Stem Cells and Tissue Engineering Group leader, Stem Cells and Cancer
Adjunct Associate Professor	Pascal	Duijf	Group Leader, Genomics and Informatics
Adjunct Professor	Neha	Gandhi	Advance Queensland Industry Research Fellow Group Leader, Biomolecular Modelling within the Cancer and Ageing Research Program
Honorary Associate Professor	Richard	Gordon	Group Leader, Translational Neuroscience
Dr	Jennifer	Gunter	Senior Research Fellow Group Leader, Cancer Metabolism within APCRC-Q
Dr	Sonia	Henriques	Senior Lecturer Group Leader, Peptide Therapeutics and Membrane Biology
Dr	Brett	Hollier	Senior Research Fellow Group Leader, Invasion and Metastasis Laboratory, within APCRC-Q
Associate Professor	Katharine (Kate)	Irvine	Irvine Group Leader, Innate Immunity & Inflammation
Associate Professor	Paul	Leo	Principal Research Fellow Senior Bioinformatician, Australian Translational Genomics Centre
Associate Professor	Simon	McIlroy	ARC Future Fellow Team Leader within the Centre for Microbiome Research
Professor	Colleen	Nelson	Executive Director, APCRC-Q
Professor	Kenneth (Ken)	O'Byrne	Professor, Medical Oncology Clinical Lead, Cancer and Ageing Research program Clinical Director, Australian Translational Genomics Centre Consultant Medical Oncologist, Metro South Health
Dr	Jatin	Patel	National Heart Foundation Future Leader Fellow Group Leader, Vascular Regeneration and Repair Group within the Cancer and Ageing Research Program
Dr	Lisa	Philp	Advance Queensland Industry Research Fellow – Mid Career Group Leader, Translational Adipokine Group within APCRC-Q

Appendix/

Queensland University of Technology Continued

TITLE	FIRST NAME	SURNAME	POSITION
Associate Professor	Pamela	Pollock	Principal Research Fellow Group Leader, Endometrial Cancer
Professor	Derek	Richard	Chenhall Research Scientist and Principal Research Fellow Scientific Director, Cancer and Ageing Research Program Director, Queensland Centre for Drug Discovery
Dr	Aaron	Smith	Senior Lecturer Group Leader, Melanoma Group
Associate Professor	Sally-Anne	Stephenson	Group Leader, Protein Ablation Cancer Therapeutics
Professor	Nathan	Subramaniam	NHMRC Senior Research Fellow and Research Capacity Building Professor Group Leader, Hepatogenomics Research
Professor	Erik (Rik)	Thompson	Professor of Breast Cancer Research Group Leader, Invasion and Metastasis Unit
Professor	Gene	Tyson	Professor of Microbial Genomics ARC Future Fellow Director, Centre for Microbiome Research Co-founder, Non-Executive Director, Microba Life Sciences
Professor	Ian	Vela	Lead Clinician, Queensland Bladder Cancer Initiative Urologic Oncologist, Princess Alexandra Hospital Urologic Oncologist, Urocology
Professor	David	Waugh	Head, School of Biomedical Sciences Group Leader, GU Precision Cancer Medicine
Associate Professor	Elizabeth	Williams	Head, Tumour Models Group Leader, Queensland Bladder Cancer Initiative
Associate Professor	Ben	Woodcroft	Senior Research Fellow Team Leader within the Centre for Microbiome Research

Appendix/

University of Queensland

TITLE	FIRST NAME	SURNAME	POSITION
Dr	Aideen	McInerney-Leo	Senior Research Fellow
Professor	Andrew	Barbour	Professor and Academic General Surgeon, Group Leader
Associate Professor	Andrew	Brooks	Associate Professor and Senior Principal Research Fellow
Professor	Antje	Blumenthal	Professor and Professorial Research Fellow
Dr	Arutha	Kulasinghe	Senior Research Fellow
Professor	Brandon	Wainwright	Professor, ARC Laureate Fellow

Appendix/
University of Queensland Continued

TITLE	FIRST NAME	SURNAME	POSITION
Dr	Colm	Keane	NHMRC Emerging Leadership Fellow
Professor	Di	Yu	Chair in Paediatric Immunotherapy, Professorial Research Fellow
Associate Professor	Emma	Hamilton-Williams	Associate Professor and Senior Principal Research Fellow
Associate Professor	Fernando	Guimaraes	Associate Professor and Senior Principal Research Fellow
Associate Professor	Fiona	Simpson	Associate Professor and Senior Principal Research Fellow
Professor	Gabrielle	Belz	Chair in Immunology, Professor and Professorial Research Fellow
Associate Professor	Graham	Leggatt	Senior Lecturer, Associate Professor in Immunology, Director (Research Training)
Associate Professor	Helmut	Schaider	Associate Professor Dermatology, Course Coordinator
Emeritus Professor	Ian	Frazer	Emeritus Professor
Associate Professor	James	Wells	Associate Professor and Senior Principal Research Fellow
Dr	Janin	Chandra	Senior Research Fellow
Dr	Jazmina	Gonzalez Cruz	Senior Research Fellow
Honorary Professor	John	Upham	Professor of Respiratory Med (Sec)
Professor	Kiarash	Khosrotehrani	Professor and Professorial Research Fellow
Professor	Mark	Morrison	Chair in Metagenonics
Dr	Mathew	Jones	Senior Research Fellow
Emeritus Professor	Michael	Roberts	Emeritus Professor
Professor	Michael	Stowasser	Affiliate Professor
Dr	Mitchell	Stark	UQ Amplify Researcher, Course Coordinator, Skin Cancer
Professor	Nikolas	Haass	Professor and Director (Research Training)
Professor	Ranjeny	Thomas	Arthritis Qld Chair of Rheumatology, Professor
Dr	Chris	Slape	Senior Research Fellow
Associate Professor	Raymond	Steptoe	Honorary Associate Professor
Associate Professor	Rik	Sturm	NHMRC Senior Research Fellow
Dr	Snehlata	Kumari	Senior Research Fellow
Dr	Timothy	Wells	Senior Research Fellow in HMR
Dr	Yousuf	Mohammed	Senior Research Fellow

Appendix/

Metro South Health Hospital & Health Services (& UQ)

TITLE	FIRST NAME	SURNAME	POSITION
Associate Professor	Stefan	Blum	Associate Professor, Princess Alexandra Hospital Southside Clinical Unit, Faculty of Medicine, UQ Staff Specialist, Neurology, Princess Alexandra Hospital
Professor	Carmel	Hawley	Senior Staff Specialist, Director Haemodialysis Services, Princess Alexandra Hospital
Associate Professor	Ingrid	Hickman	Principal Research Fellow, Department of Nutrition and Dietetics, Princess Alexandra Hospital Southside Clinical Unit, Faculty of Medicine, UQ
Professor	Gerald	Holtman	Director, Department of Gastroenterology and Hepatology, Princess Alexandra Hospital Director of Clinical Innovation – UQ Faculty of Medicine and Faculty of Health and Behavioural Sciences
Professor	David	Johnson	Director, Metro South and Ipswich Nephrology and Transplant Service (MINTS) Medical Director, Queensland Renal Transplant Service, The Princess Alexandra Hospital NHMRC Leadership Fellow, Professor of Medicine and Professor of Population Health, UQ Director, Centre for Kidney Disease Research, Faculty of Medicine, UQ
Professor	Kenneth (Ken)	O'Byrne	Professor, Faculty of Health, QUT Staff Specialist, Oncology, Princess Alexandra Hospital
Professor	Ben	Panizzo	Professor, Princess Alexandra Hospital Southside Clinical Unit, Faculty of Medicine, UQ Staff Specialist, Ear, Nose and Throat, Princess Alexandra Hospital
Professor	Elizabeth	Powell	Senior Staff Specialist, Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Director, Centre for Liver Disease Research, Princess Alexandra Hospital Southside Clinical Unit, Faculty of Medicine, UQ
Professor	John	Upham	Professor of Respiratory Medicine, Princess Alexandra Hospital Southside Clinical Unit, Faculty of Medicine, UQ Director, Lung and Allergy Research Centre Executive Director, Metro South Health Research
Dr	Michael	Wagels	Staff Specialist Plastic and Reconstructive Surgeon and Deputy Director, Department of Plastic and Reconstructive Surgery, Princess Alexandra Hospital Director, ACCISS, TRI Senior Lecturer, UQ Clinical Directory, Herston Biofabrication Institute

Acronyms and Abbreviations

AAMRI	Association of Australian Medical Research Institutes
ACCISS	Australian Centre for Complex Integrated Surgical Solutions
AIBN	Australian Institute for Bioengineering and Nanotechnology
ARC	Australian Research Council
BRF	Biological Resources Facility
CAN	Clinical Alliance Network
CHO	Chief Health Officer
CHQ	Children's Health Queensland
CI	Co-investigator
CRC	Cooperative Research Centre
CRF	Clinical Research Facility
ELT	Executive Leadership Team
FDA	Food and Drug Administration
FTE	Full time equivalent
GMP	Good manufacturing practice
HR	Human resources
HTQ	Health Translation Queensland
ICT/IT	Information (and Communication) Technology
LINC	Leading Innovations through New Collaborations
LSQ	Life Sciences Queensland
MP	Member of Parliament
MR/MRI	Magnetic resonance (imaging)
MRFF	Medical Research Future Fund
MSH	Metro South Health
MTP	Medical technology, biotechnology and pharmaceutical
NHMRC	National Health and Medical Research Council
PAH	Princess Alexandra Hospital
PI	Principal investigator
QUT	Queensland University of Technology
RHO	Research House Officer
RNA	Ribonucleic acid
RTC	Research Translation Committee
SHAP	Sexual Harassment Awareness and Prevention Committee
SLC	Shared Leadership Committee
SOC	Shared Operations Committee
SPARQ-ed	Students Performing Advance Research Queensland
TM@TRI	Translational Manufacturing at TRI
TRI	Translational Research Institute
TRIC	TRI at Children's
UQ	The University of Queensland
UQCHR	University of Queensland Centre for Health Services Research
UQFI	The University of Queensland Frazer Institute
WHS	Workplace Health and Safety

TRI

TRANSLATIONAL RESEARCH INSTITUTE
AUSTRALIA

PARTNERS

The University Of Queensland
AUSTRALIA

QUT

mater
research

Queensland
Government

Queensland Health